TRICHLOROETHYLENE EXPOSURE AND TRAUMATIC BRAIN INJURY INTERACT AND PRODUCE DUAL INJURY BASED PATHOLOGY AND PIOGLITAZONE CAN ATTENUATE DEFICITS FOLLOWING TRAUMATIC BRAIN INJURY by Sauerbeck, Andrew David
University of Kentucky 
UKnowledge 
University of Kentucky Doctoral Dissertations Graduate School 
2011 
TRICHLOROETHYLENE EXPOSURE AND TRAUMATIC BRAIN 
INJURY INTERACT AND PRODUCE DUAL INJURY BASED 
PATHOLOGY AND PIOGLITAZONE CAN ATTENUATE DEFICITS 
FOLLOWING TRAUMATIC BRAIN INJURY 
Andrew David Sauerbeck 
University of Kentucky, sauerbecka@gmail.com 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Sauerbeck, Andrew David, "TRICHLOROETHYLENE EXPOSURE AND TRAUMATIC BRAIN INJURY 
INTERACT AND PRODUCE DUAL INJURY BASED PATHOLOGY AND PIOGLITAZONE CAN ATTENUATE 
DEFICITS FOLLOWING TRAUMATIC BRAIN INJURY" (2011). University of Kentucky Doctoral Dissertations. 
133. 
https://uknowledge.uky.edu/gradschool_diss/133 
This Dissertation is brought to you for free and open access by the Graduate School at UKnowledge. It has been 
accepted for inclusion in University of Kentucky Doctoral Dissertations by an authorized administrator of 
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
  
 
 
 
 
Abstract of Dissertation 
 
 
 
 
 
Andrew D. Sauerbeck 
 
 
 
 
 
The Graduate School 
University of Kentucky 
2011 
 
 
 
 
 
  
 
 
 
 
 
TRICHLOROETHYLENE EXPOSURE AND TRAUMATIC BRAIN INJURY INTERACT  
AND PRODUCE DUAL INJURY BASED PATHOLOGY AND PIOGLITAZONE  
CAN ATTENUATE DEFICITS FOLLOWING TRAUMATIC BRAIN INJURY 
 
 
 
 
_______________________________________________ 
 
ABSTRACT OF DISSERTATION 
_______________________________________________ 
 
A dissertation submitted in partial fulfillment of the 
requirements for the degree of Doctor of Philosophy in the 
College of Medicine at the University of Kentucky 
By 
Andrew David Sauerbeck 
Lexington, Kentucky 
Director: Dr. Patrick G. Sullivan,  
Professor of Anatomy and Neurobiology 
Lexington, Kentucky 
 
2011 
 
 
Copyright © Andrew David Sauerbeck 2011 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT OF DISSERTATION 
 
 
 
 
TRICHLOROETHYLENE EXPOSURE AND TRAUMATIC BRAIN INJURY INTERACT  
AND PRODUCE DUAL INJURY BASED PATHOLOGY AND PIOGLITAZONE  
CAN ATTENUATE DEFICITS FOLLOWING TRAUMATIC BRAIN INJURY 
 
 
 The development of Parkinson's disease (PD) in humans has been linked to genetic and 
environmental factors for many years. However, finding common single insults which can 
produce pathology in humans has proved difficult. Exposure to trichloroethylene (TCE) or 
traumatic brain injury (TBI) has been shown to be linked to PD and it has also been proposed 
that multiple insults may be needed for disease development. 
 The present studies show that exposure to TCE prior to a TBI can result in pathology 
similar to early PD and that the interaction of both insults is required for impairment in 
behavioral function, and cell loss. Following exposure to TCE for 2 weeks there is a 75% 
impairment in mitochondrial function but it has yet to be shown if the addition of a TBI can make 
this worse. If the exposure to TCE is reduced to 1 week and combined with TBI a 50% reduction 
in mitochondrial function is observed following the dual injury which requires both insults. These 
studies provide further support for the hypothesis that PD may result from a multifactorial 
mechanism. 
 It had been established that regional differences exist in mitochondrial function across 
brain regions. The present studies indicate that previous findings are not likely to be the result of 
differences in individual mitochondria isolated from the cortex, striatum, and hippocampus. 
Further analysis of the effect of mitochondrial inhibitors on enzyme activity and oxygen 
consumption reveal that the different regions of the brain are similarly affected by the inhibitors. 
These results suggest that findings from previous studies indicating regionally specific deficits 
following systemic toxin exposure, such as with TCE, are not the result of regional differences in 
the individual mitochondria. 
 Given that TBI results in significant dysfunction, finding effective therapeutics for TBI will 
provide substantial benefits to individuals suffering an insult. Treatment with Pioglitazone 
following TBI reduced mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and 
inflammation. These findings provide initial evidence that treatment with Pioglitazone may be an 
effective intervention for TBI.  
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Chapter 1 
Introduction 
Mitochondria 
Normal physiological function: 
 The mitochondrion is a cellular organelle composed of two lipid bilayers, the 
inner and outer mitochondrial membranes, and complex protein machinery necessary to 
produce large amounts of adenosine-triphosphate (ATP), a required substrate for 
numerous cellular functions. Historically, mitochondria were independent bacteria which 
were incorporated into mammalian cells, leading to the ability for complex organisms to 
develop (Lane, 2006). Prior to becoming part of the mammalian cell, the mitochondria 
had a large genome containing thousands of genes (Timmis et al., 2004). Through many 
years of evolution, mammalian mitochondria now only contain 37 genes and require 
genes encoded in the nucleus for 99% of all mitochondrial proteins (Lane, 2006). The 
production of ATP by the mitochondria requires electrons to be moved sequentially 
through a series of proteins resulting in the generation of a proton gradient (Figure 
1.1)(Nicholls and Ferguson, 2002). The inter-membrane space (IMS) lies between the 
inner and outer mitochondrial membranes and protons are “pumped” here during 
mitochondrial respiration. The process of moving protons from the matrix, the area inside 
of the inner mitochondrial membrane, into the IMS utilizes energy from the flow of 
electrons through the electron transport chain (ETC). As an electron moves through the 
ETC, the energy level of the electron decreases as protons are pumped into the IMS 
(Figure 1.2). In order for the mitochondria to obtain a high energy electron, food from the 
diet is first broken down and metabolized into smaller molecules, such as glucose, which 
can be further processed by the cell. The process of glycolysis converts  
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Figure 1.1 Diagram of electron transport chain 
 
The mitochondrial electron transport chain (ETC) utilizes high energy electrons to move 
protons from the mitochondrial matrix into the intermembrane space. Electrons enter the 
ETC through Complex I and Complex II as the result of the oxidation of NADH and 
FADH2. Electrons move from Complexes I and II via Ubiquinone (CoQ10) to Complex III 
and from Complex III to Complex IV via Cytochrome C. As electrons are transferred 
through the ETC, protons are moved through Complexes I, III, and IV generating a 
proton concentration gradient. The mitochondrial membrane potential, generated by the 
concentration of protons in the intermembrane space, is utilized by Complex V to 
generate ATP. 
 
Figure 1.2: Diagram of decrease in electron energy level 
 
The proteins of the mitochondrial electron 
transport chain (ETC) have different redox 
potentials which range from ~-300mV at 
Complex I to ~600mV at Complex V. The 
sequential change in redox potential facilitates 
the directional flow of electrons through the 
ETC. As the electrons are moved through the 
ETC, the energy state of the electron is reduced 
significantly as a result of the usage of energy to 
translocate protons from the mitochondrial 
matrix to the intermembrane space 
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glucose into pyruvate through a process of ten enzymatic steps. Pyruvate can be further 
processed in the mitochondrial matrix by the tricarboxylic acid cycle (TCA cycle) in order 
to produce NADH and FADH2. Complex I (NADH-Ubiquinone Oxidoreductase) can 
oxidize NADH to NAD+ by transferring an electron from NADH to an iron-sulphur (Fe-S) 
center which resides in Complex I. This first electron transfer results in the movement of 
protons into the IMS. Complex II (Succinate Dehydrogenase) can oxidize the FADH2 
produced by the TCA cycle into FAD in a similar manner to the oxidation of NADH by 
Complex I. Even though Complex II does receive an electron from FADH2 no proton 
translocation to the IMS occurs during this step. Both Complexes I and II can then 
transfer the electron obtained from either NADH or FADH2 to Complex III via ubiquinone 
(Coenzyme Q10), which resides in the IMS. Complex III can subsequently transfer the 
electron to Cytochrome C and move additional protons into the IMS. Cytochrome C then 
transfers the electron to Complex IV (Cytochrome C Oxidase), which is able to utilize 
energy from the electron to move an additional four protons into the IMS while 
consuming oxygen in the form of O2. The consumption of oxygen by Complex IV results 
in the formation of two molecules of water and the elimination of four electrons. The 
process by which electrons move through the ETC from complex to complex while 
“pumping” protons into the IMS results in the formation of a mitochondrial membrane 
potential (ΔΨ). As a result of the generated ΔΨ, Complex V (ATP Synthase) is able 
harness the energy in the proton gradient by allowing protons to flow down the proton 
concentration gradient and through Complex V, resulting in the production of ATP. The 
mitochondrial respiratory process is vital to normal cellular function and survival and 
even transient inhibition of the process can lead to a loss of ATP and cell death. 
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Regional differences in basal mitochondrial function: 
 Given the diversity of the nervous system and the regional differences observed 
in mitochondrial function in different experimental models, it is currently understood that 
regional differences play an important role in mitochondrial function (for review see 
(Dubinsky, 2009)). As with many other aspects of cellular function, calcium plays an 
important role in mitochondrial function. Regional differences in the levels and regulation 
of calcium can directly affect the function of the mitochondria. In response to increases 
in intracellular calcium levels, the aspartate-glutamate carrier becomes activated and 
imports NADH (Pardo et al., 2006). The increased intracellular concentration of NADH is 
thought to underlie the observed increases in activities of the α-ketoglutarate, Pyruvate, 
and oxoglutarate dehydrogenases following increases in intracellular calcium (Denton et 
al., 1988). In addition to calcium induced changes in the activities of some of the 
dehydrogenases, regional differences have also been observed for Malate 
dehydrogenase and creatine kinase (Ryder, 1980, Gupta et al., 2000). In addition basal 
differences, neuronal activity has been shown to transcriptionally regulate mitochondrial 
subunit expression (Wong-Riley et al., 1997). Reducing neuronal activity with the 
application of tetrodotoxin has been shown to result in a loss of Cytochrome C oxidase 
levels (Nie and Wong-Riley, 1996), further indicating a close relationship between levels 
of neuronal activity and mitochondrial function. An additional difference in mitochondrial 
function between different regions of the brain can be observed by comparing spare 
respiratory capacity, which is the ability for mitochondria to increase the respiratory rate. 
Fern compiled data from many sources in order to compare the amount of spare 
respiratory capacity across brain regions and across mitochondrial complexes. It was 
observed that regions of the brain such as the striatum, which are highly metabolically 
active, have relatively lower levels of spare respiratory capacity (Fern, 2003), indicating 
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that even though mitochondrial subunit levels are correlated with neuronal activity there 
may be an upper limit to the amount of mitochondrial function for a given brain region. 
One of the most striking findings from Fern’s analysis is that the regions with the lowest 
spare respiratory capacity for a given mitochondrial complex are also the regions of the 
brain which are the most susceptible to mitochondrial inhibitors which block that 
complex. The striatum was the next to lowest region of the brain with regards to 
Complex II spare respiratory capacity (Fern, 2003) and this is also a region of the brain 
highly susceptible to the Complex II inhibitor 3-Nitropropionic acid (Beal et al., 1993). 
Further evidence supporting the existence of regional differences in brain mitochondria 
comes from work looking at the response of mitochondria to ischemic insults. Following 
a 30 minute ischemic event and six hours of reperfusion the paramedian cortex exhibited 
no decrease in mitochondrial function while the dorsal-lateral striatum exhibited 
approximately a 25% decrease in mitochondrial state 3 function (Sims, 1991), further 
indicating that the striatum is more susceptible to bioenergetic inhibition. 
Synaptic vs. non-synaptic mitochondrial function: 
 In addition to different regions of the brain exhibiting differences in mitochondrial 
function, differences have been observed between synaptic and non-synaptic 
mitochondria from the same region of the brain (Davey et al., 1997, Brown et al., 2006, 
Naga et al., 2007, Pathak and Davey, 2008). By using inhibitors specific for Complexes 
I, III, and IV the susceptibility of synaptic and non-synaptic mitochondria to mitochondrial 
inhibition has been investigated. Synaptic mitochondria isolated from the whole brain are 
markedly more susceptible to Complex I inhibition by rotenone than non-synaptic 
mitochondria (Pathak and Davey, 2008). Non-synaptic mitochondria required a 72% 
inhibition of Complex I before any changes were observed in mitochondrial oxygen 
consumption while synaptic mitochondria began showing mitochondrial respiration 
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deficits after only 25% inhibition of Complex I (Pathak and Davey, 2008). In contrast to 
the large differences between synaptic and non-synaptic mitochondria with regards to 
Complex I inhibition and mitochondrial oxygen consumption, no major differences are 
observed between Complex III and Complex IV inhibition and mitochondria oxygen 
consumption with tissue isolated from the whole brain  (Pathak and Davey, 2008). When 
looking within sub-regions of the brain, the cortex and CA1 region of the hippocampus 
exhibit similar effects of Complex I inhibition with both regions showing that synaptic 
mitochondria show oxygen consumption deficits with only 25% inhibition of Complex I 
while non-synaptic mitochondria require 60% inhibition (Pathak and Davey, 2008). In 
addition to being more susceptible to mitochondrial Complex I inhibition, synaptic 
mitochondria have also been shown to regulate calcium differently than non-synaptic 
mitochondria (Brown et al., 2006, Naga et al., 2007). Synaptic mitochondria isolated 
from cortical tissue are not able to buffer as much calcium as non-synaptic mitochondria 
before undergoing mitochondrial permeability transition pore (mPTP) formation (Brown 
et al., 2006). Even the addition of Cyclosporine A, which can inhibit the formation of the 
mPTP, cannot raise the calcium buffering capacity of synaptic mitochondria up to that of 
basal non-synaptic mitochondria (Brown et al., 2006). Further evidence shows that the 
major underlying difference between synaptic and non-synaptic mitochondrial calcium 
buffering capacity resides in the significantly higher levels of Cyclophilin D in synaptic 
mitochondria (Naga et al., 2007). Removing Cyclophilin D from synaptic mitochondria by 
utilizing knockout mice results in an increase in the calcium buffering capacity of the 
synaptic mitochondria to that of wild-type non-synaptic mitochondria (Naga et al., 2007). 
The collection of findings looking at synaptic and non-synaptic mitochondria further 
defines the significance of regional differences in mitochondrial function since not only 
are there differences among mitochondria from different areas of the brain but there are 
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differences in mitochondria between different portions of the cellular architecture of a 
given brain region, specifically synaptic and non-synaptic regions. 
Regional mitochondrial differences following systemic toxin exposure: 
 An important aspect of regionally specific mitochondrial differences can be 
observed following the systemic administration of mitochondrial toxins, where specific 
regions of the brain are more affected by a given toxin. The toxins 3-nitropropionic acid 
(3-NP), cyanide, and trichloroethylene (TCE) have all been shown to inhibit 
mitochondrial function and produce regionally specific damage following systemic 
administration (Hicks, 1950, Beal et al., 1993, Gash et al., 2008, Liu et al., 2010). The 
toxin 3-NP irreversibly inhibits Complex II (succinate dehydrogenase)  of the 
mitochondrial electron transport chain (Alston et al., 1977) and systemic exposure to 3-
NP produces an excitotoxic lesion in the striatum but not in other regions of the brain 
(Beal et al., 1993). Regional differences in how the mitochondria are affected and 
regulated following exposure to 3-NP may underlie the observed regionally specific 
susceptibility to 3-NP. Following exposure to 3-NP, striatal neurons but not cortical 
neurons up regulate Cytochrome-C oxidase (COX) levels which results in increases in 
ATP levels with the side effect of increased peroxide production, leading to increases in 
oxidative stress (Singh et al., 2010). Additionally, the striatum has been shown to have 
one of the lowest spare respiratory capacities for Complex II of any brain region 
accessed (Fern, 2003) and this may drive a proportionally higher degree of energy 
impairment in the striatum following exposure to 3-NP. With a lower basal spare 
respiratory capacity, mitochondrial inhibition by 3-NP likely drives the striatum to up 
regulate COX in an attempt to maintain ATP production and cell viability. Even though 
the increase in COX leads to more ATP production, the increased peroxide production 
would make the cells more vulnerable and play a role in the cell loss observed in the 
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striatum (Singh et al., 2010). Similar to 3-NP, TCE has been shown to produce regionally 
specific deficits following systemic administration (Gash et al., 2008, Liu et al., 2010). 
Following six weeks of TCE exposure in rats, mitochondrial bioenergetic impairment was 
observed in the substantia nigra but not in the striatum or liver (Gash et al., 2008). At 
both two and six weeks following exposure to TCE there are increases in markers of 
oxidative stress in the substantia nigra along with significant impairment in mitochondrial 
Complex I activity (Liu et al., 2010). In the striatum there is an increase in Complex I 
activity following six weeks of TCE exposure (Gash et al., 2008) and this may represent 
a compensatory response similar to the striatal increase in COX following 3-NP 
exposure (Singh et al., 2010). In addition to predominately affecting mitochondria 
bioenergetic function in the substantia nigra after six weeks of exposure, TCE also 
results in death of dopaminergic neurons but not cholinergic or GABAergic neurons (Liu 
et al., 2010), further expanding the level of complexity in regional mitochondrial deficits 
to including cell type specific responses. Cyanide, a mitochondrial Complex IV inhibitor, 
has also been shown to produce regionally specific damage, most notably to white 
matter (Hicks, 1950), and like 3-NP its toxicity is correlated the amount of spare 
respiratory capacity for the region it affects (Fern, 2003). Exposure to cyanide does 
affect mitochondrial functions in other regions, such as the cortex where reductions in 
COX activity and ATP levels are observed shortly after exposure (MacMillan, 1989), 
however, the long term damage still remains mainly in the white matter of the corpus 
callosum following sub lethal exposure (Brierley et al., 1976). The major apparent 
similarity observed with the different toxin models is that pathology tends to follow basal 
differences in mitochondrial function and regional requirements for energy sources. 
Regions which have lower levels of spare mitochondrial respiratory capacity for a given 
mitochondrial complex are more likely to show damage following exposure to a toxin 
inhibiting that complex. Additionally, cell populations with high energy demands, such as 
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dopamine neurons, are more susceptible to inhibition of mitochondrial function than 
other cell types from the same brain region (Zeevalk et al., 1997). Brain regions which 
cannot maintain sufficient mitochondrial function and ATP production can become 
damaged and undergo cell loss while regions which can maintain sufficient energy 
production survive. 
Pathological mitochondrial function: 
 The complexity of the electron transport chain process leaves the system 
vulnerable to many insults and disturbances. For example, following TBI an ischemic 
insult can result in a loss of oxygen needed by the mitochondria at Complex IV to 
remove electrons from the ETC. Following reperfusion of the hypoxic tissue with 
oxygenated blood there is a rapid increase in the production of reactive oxygen species 
(ROS) which can overcome endogenous antioxidant systems and lead to further 
damage and dysfunction (for review see (Sugawara and Chan, 2003)). Given its critical 
role in normal cellular function by producing ATP, the mitochondria's susceptibility to a 
wide range of inhibitors and insults, and its ability to initiate cell death cascades, it is not 
surprising that the mitochondria has been found to play an important role in numerous 
pathological conditions. Mitochondrial dysfunction has been observed following TBI or 
exposure to environmental toxins such as TCE as well as in degenerative neurological 
conditions such as Parkinson's disease (PD). The role the mitochondria plays in these 
separate yet related pathologies is discussed in more detail in the sections specific to 
each insult/pathology. 
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Traumatic brain injury 
Epidemiology: 
 Every year in the United States there are approximately 1.7million individuals that 
obtain medical care at a hospital emergency department (ED) for treatment related to a 
traumatic brain injury (TBI) (Faul et al., 2010).  Of the individuals that go to an ED for  
care related to a TBI, approximately 52,000 die, 275,00 become hospitalized, and 1.36 
million are released (Faul et al., 2010). The level of severity for a TBI can vary 
significantly between individuals with some people sustaining a mild TBI with short term 
alterations in cognition and mental status to individuals having a severe TBI which 
results in chronic long term disability and impairment. Current estimates predict that in 
the United States there are approximately 5.3 million individuals living with prolonged 
deficits due to a TBI (Thurman et al., 1999). The prolonged impairments from a TBI can 
affect multiple aspects of normal daily function including cognition, sensorimotor 
function, language, and emotion (NINDS, 2002). The four most common causes of TBI 
are falls (28%), motor vehicle accidents (20%), impact with an object (19%), and 
assaults (11%) (Figure 1.3)(Langlois et al., 2006). Not only does TBI impart significant 
hardships on the individual sustaining the injury but it is also estimated that in the United 
States alone TBIs cost $60 billion annually as a result of medical expenses and lost 
productivity (Finkelstein et al., 2006).  The incidence of TBI can vary widely between 
gender, ethnic, and age groups, and  men are twice as likely as women to sustain a TBI 
(Langlois et al., 2006). On average people over the age of 75 are more likely to die from 
a TBI and African Americans have the highest likelihood of death compared to other 
ethnic backgrounds (Langlois et al., 2006). The primary cause of a TBI can vary widely 
and plays a direct and important role in the pathology which ensues. 
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Figure 1.3: Causes of traumatic brain injury 
 
Traumatic brain injury (TBI) results from various different causes. The most common 
mechanisms leading to TBI pathology are falls, motor vehicle accidents, impact with an 
object, and assaults. These four causes are responsible for 78% of all TBIs in the United 
States.  
 
 
Primary injury mechanisms: 
 TBI pathology results from both a primary injury and a secondary injury cascade. 
The primary injury is due to biomechanical damage which results in the shearing and 
compression of neuronal, glial, and vascular tissue. TBIs can result from numerous 
different causes (Figure 1.3), present with a variety of different anatomical pathologies, 
and present with injury levels ranging from mild to severe. Current research on human 
TBI has generally utilized neurological injury severity criteria to classify the severity of 
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the injury (Narayan et al., 2002, Saatman et al., 2008) with the 15-point Glasgow Coma 
Score (GCS) (Teasdale and Jennett, 1974) being the most common (Narayan et al., 
2002). Though the GCS has been utilized extensively for clinical trials seeking to enroll 
patients with severe TBIs, the GCS does not work well for certain populations such as 
infants, it does not distinguish less severe injuries, and it cannot distinguish the 
underlying type of injury (Saatman et al., 2008). Beyond determining the severity of a 
TBI, it is important to understand the causative mechanism of the injury since different 
types of injuries require different medical care and have different long term outcomes. 
TBI can result in various neuroanatomical changes which include epidural hematoma, 
parenchymal hematoma, diffuse axonal injury (DAI), subdural hematoma, subarachnoid 
hemorrhage, intraventricular hemorrhage, and diffuse brain swelling (Saatman et al., 
2008). Of the various primary injuries, the four main pathologies observed in human TBI 
are subarachnoid hemorrhage,  DAI, contusion, and hematoma (Saatman et al., 2008). 
Patients can present with any combination of pathoanitomical changes or even just a 
single injury type.  It was recently shown that patients presenting with an initial GCS <8, 
indicating a severe TBI, can exhibit single injury types which cannot be distinguished by 
the GCS score (Saatman et al., 2008). The problems associated with utilizing a GCS 
score for patient treatment decisions indicates that new strategies for rapidly classifying 
injury type need to be found since the type of injury affects patient outcome (Gennarelli 
et al., 1982). Given the variety of types of injuries, it is crucial to understand what type of 
injury a patient has so that appropriate medical care can be given. 
Secondary injury mechanisms: 
 The cascade of secondary injury damage, which occurs in the hours and days 
following the initial insult, is due to activation of pathophysiological cascades, consisting 
of complex biochemical and cellular pathways that influence progression of the injury. 
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Secondary injury processes include alterations in excitatory amino acids (Yamamoto et 
al., 1999, Rose et al., 2002), increased reactive oxygen species (ROS) production 
(Marklund et al., 2001, Hall et al., 2004, Tavazzi et al., 2005), disruption of calcium 
homeostasis (Mattson and Scheff, 1994, Xiong et al., 1997, Sullivan et al., 1999c), post-
traumatic neuroinflammation (Morganti-Kossmann et al., 2001, Vlodavsky et al., 2006) 
and mitochondrial dysfunction (Azbill et al., 1997, Xiong et al., 1997, Sullivan et al., 
1998b, Sullivan et al., 1999a, Sullivan et al., 1999b). As a result of these secondary 
injury processes, there are significant reductions in ATP levels (Sullivan et al., 1998a), 
increases in lipid peroxidation (Sullivan et al., 1998a), release of Cytochrome C (Sullivan 
et al., 2002) and activation of apoptotic pathways (Sullivan et al., 2002),  all of which can 
lead to the initiation of cell death pathways.   
Mitochondrial dysfunction following traumatic brain injury: 
 Mitochondria are a major component of this secondary injury pathway because 
they function as a highly sensitive regulator of cell death mechanisms and as the primary 
energy producer for the cell. The mitochondria play a pivotal role in cerebral energy 
metabolism, intracellular calcium homeostasis, and ROS generation and detoxification. 
Following TBI, a significant disruption of mitochondrial homeostasis has been 
documented that results in a decline in cellular bioenergetics, increased mitochondrial 
ROS production and a decline in synaptic equilibrium (Azbill et al., 1997, Xiong et al., 
1997, Sullivan et al., 1998b, Sullivan et al., 1999a, Sullivan et al., 1999b). Immediately 
after the TBI reductions in the amount of ATP have been observed in the cortex 
following a cortical impact brain injury and this impairment in mitochondrial function 
precedes increases in levels of lipid peroxidation which begin to increase by 30 minutes 
post injury (Sullivan et al., 1998b).  
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Looking at more detailed mechanisms of the mitochondrial dysfunction which occurs 
after TBI has revealed that in cortical synaptosomes isolated 30 minutes after the injury 
there is a loss of mitochondrial membrane potential, increases in intracellular 
mitochondrial calcium loading, increased susceptibility to calcium induced mitochondrial 
permeability transition, and increases in the production of ROS (Sullivan et al., 1999c). 
The mitochondrial deficits which occur after the injury can lead to both mitochondrial and 
cellular damage and dysfunction. The loss of the mitochondria’s ability to produce ATP 
can impair the cell’s ability to maintain both normal and post-injury functions and 
ultimately lead to cell death (Nicholls and Budd, 2000). Additionally, factors such as 
mitochondrial ROS production and increases in levels of mitochondrial lipid peroxidation 
can result in mitochondrial bioenergetic impairments resulting in further reductions in 
mitochondrial dependent ATP production as well as the induction of mitochondrial 
dependent cell death pathways (Nicholls and Budd, 2000). Considering the multiple 
mechanisms of mitochondrial dysfunction that occur following TBI, the degree of 
mitochondrial injury or dysfunction can be an important determinant of cell survival or 
death (for reviews see (Robertson, 2004, Sullivan et al., 2005, Robertson et al., 2006) 
and it has been shown that therapeutic treatments designed to protect and stabilize the 
mitochondria have the ability to reduce injury in preclinical studies (Sullivan et al., 2000a, 
Pandya et al., 2007).  
Mitochondrial treatments for traumatic brain injury: 
 Given the important role which the mitochondria play in both normal and post-TBI 
pathology, and the desire to find therapeutic interventions which result in 
neuroprotection, drugs targeting mitochondrial function have been pursued as potential 
effective interventions.  Mitochondrial therapeutics which have been pirsued for the 
treatment of TBI include Cyclosporine A (CsA), mitochondrial uncouplers such as 2,4-
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Dinitrophenol (2,4-DNP) and FCCP, as well as alternative energy sources for the 
mitochondria. 
 Cyclosporin A is an immunosuppressive drug which is capable of binding to 
mitochondrial Cyclophilin D thereby inhibiting the formation of mitochondrial permeability 
transition pore (mPTP) (Broekemeier et al., 1989, Broekemeier and Pfeiffer, 1995). 
Following TBI there is significant mitochondrial dysfunction which occurs acutely after 
the injury (Sullivan et al., 1998b, Sullivan et al., 1999c, Sullivan et al., 2004). Treatment 
with CsA 15 minutes after a TBI has shown the ability to ameliorate multiple aspects of 
mitochondrial pathology by preventing the formation of the mPTP, preserving membrane 
potential, reducing mitochondrial calcium accumulation, and reducing the production of 
mitochondrial ROS (Sullivan et al., 1999c). It has also been observed that treatment with 
CsA is capable of reducing the amount of cortical tissue loss by up to 50% following a 
single bolus injection (Sullivan et al., 1999c) and up to 74% following a continuous 
infusion of CsA (Sullivan et al., 2000c). Further work has indicated that significant 
mitochondrial improvements can still be obtained even if treatment with CsA is delayed 
for 24 hours following the injury (Sullivan et al., 2000b), which should provide a large 
therapeutic window of opportunity for the usage of CsA in humans. Confirming the 
mitochondrial findings observed with CsA treatment, administration of the non-
immunosuppressive CsA analog NIM811 was shown to protect the mitochondria 
following TBI (Mbye et al., 2008). Treatment with NIM811 resulted in preservation of the 
mitochondrial respiratory control ratio (RCR), mitochondrial bioenergetic function, and 
prevented increases in the oxidative damage markers 4-hydroxynonenol (4-HNE) and 3-
Nitrotyrosine (3-NT) (Mbye et al., 2008). Given the effectiveness of CsA in preclinical 
research, the clinical testing of CsA in humans for the treatment of TBI has begun 
(Hatton et al., 2008, Mazzeo et al., 2009). 
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 A second therapeutic intervention targeting the mitochondria is the use of 
chemical mitochondrial uncouplers. Mitochondrial uncoupling is a process by which 
protons are moved from the mitochondrial intermembrane space to the matrix without 
going through Complex-V of the mitochondria, thereby rapidly reducing mitochondrial 
membrane potential (for review see (Sullivan et al., 2004, Mattiasson and Sullivan, 
2006)). Given that after TBI there is a rapid increase in excitotoxicity which results in 
intracellular calcium accumulation (Fiskum, 2000) it was proposed that this calcium 
accumulation would lead to mitochondrial calcium overload (Pandya et al., 2007). The 
hypothesis was generated that treatment with mitochondrial uncouplers would reduce 
the mitochondrial calcium overload since the mitochondrial accumulation of calcium is 
membrane potential dependent (Pandya et al., 2007). A single intraperitoneal injection of 
either 2,4-DNP or FCCP five minutes after a TBI led to  reductions in the amount of 
cortical tissue loss and hippocampal Fluoro Jade-B positive neurons, and this was 
correlated with preservations in cognitive function (Pandya et al., 2007). As was 
hypothesized, animals treated with mitochondrial uncouplers exhibited preserved levels 
of mitochondrial bioenergetic function, reductions in in situ calcium loading, and 
reductions in mitochondrial ROS production (Pandya et al., 2007). Given that a five 
minute post-injury treatment time is not feasible for translating to human usage, a 
delayed time course for administration was tested (Pandya et al., 2009). Delaying the 
administration of the mitochondrial uncoupler FCCP up to six hours after the injury 
produced the same beneficial effect as observed following a five minute post-injury 
injection, indicating a broad therapeutic window of opportunity for the treatment of TBI 
with a mitochondrial uncoupler (Pandya et al., 2009). 
 Additional work has pursued the use of alternative energy sources for the 
mitochondria following TBI to maintain ATP levels. Following either a moderate or 
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severe TBI, alterations in the brain’s usage of oxygen, glucose, and lactate have been 
observed in humans which suggests the brain changes how it utilizes energy sources for 
the production of ATP (Glenn et al., 2003). Given that the brain changes how it 
generates ATP after a TBI, it was proposed by Prins et al. that administration of the 
ketone beta-hydroxybutarate(B-HB) after TBI would ameliorate energy deficits observed 
after the injury (Prins et al., 2004). Following a three hour infusion of B-HB beginning 
immediately after the injury, treatment prevented the 20% reduction in ATP levels which 
was observed in vehicle-treated injured animals (Prins et al., 2004). It was also observed 
that sham animals did not exhibit an increase in cerebral uptake of B-HB, which was 
observed in the injured animals, further suggesting that the TBI directly alters how the 
brain responds to mitochondrial energy sources and what fuel sources the brain utilizes 
after a TBI (Prins et al., 2004).  
Supporting the concept that alternative energy sources can lead to 
neuroprotection after TBI, research has shown that post-injury fasting promotes 
neuroprotection by reducing cortical tissue loss, reducing mitochondrial calcium loading, 
maintaining mitochondrial bioenergetic function, and preventing increases in oxidative 
damage (Davis et al., 2008).  Given that fasting increases both insulin and ketone levels 
in the blood, both were testing following TBI to determine if either component of post-
injury fasting was responsible for the neuroprotection. Davis et al. showed that the 
ketone B-HB but not insulin was capable of increasing tissue sparing after the injury 
(Davis et al., 2008), providing further evidence and support that following TBI providing 
the brain with alternative fuels, specifically the ketone B-HB, is capable of providing 
neuroprotection and reducing post injury deficits.  
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Excitotoxicity following traumatic brain injury: 
 The concept of excitotoxicity was developed by Olney after subcutaneous 
injections of monosodium glutamate were shown to produce neuronal loss in various 
brain regions (Olney, 1969). The mechanism of cell death resulting from glutamate 
exposure has been shown to result from the influx of calcium into the cell (Choi, 1987) 
and that the NDMA receptor but not voltage-sensitive calcium channels are the cytotoxic 
source of the calcium (Tymianski et al., 1993). It has been shown that the link between 
NMDA receptor activation and the resulting mitochondrial dysfunction results from their 
close proximity to each other (Peng and Greenamyre, 1998) and this connection results 
in the mitochondria being considered the primary cause of excitotoxic cell death 
(Fiskum, 2000). A major mechanism underlying glutamate induced damage is through 
the effects of calcium influx on the mitochondria and damage to calcium extrusion 
pathways, which inhibit mitochondrial bioenergetic function (Ward et al., 2000). Both 
aspects of mitochondrial impairment can eventually lead to cellular deregulation of 
calcium and the loss of ATP production (Figure 1.4) (Ward et al., 2000). It has further 
been shown that the increase in mitochondrial calcium concentrations is mitochondrial 
membrane potential dependent. Treatment with mitochondrial uncouplers can reduce 
the accumulation of calcium in the mitochondria following TBI (Pandya et al., 2009). 
 TBI in humans has been shown to lead to elevations in the levels of excitatory 
amino acids (EAAs), specifically the neurotransmitter glutamate, in cerebrospinal fluid 
(CSF) (Bullock et al., 1998, Koura et al., 1998, Yamamoto et al., 1999). Patients with 
elevated CSF glutamate levels have been shown to have increased post-injury 
intracranial pressure and a worse outcome six months after the injury (Koura et al., 
1998). Animal models of TBI have shown that the increases in glutamate levels are  
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Figure 1.4: Excitotoxic calcium induced mitochondrial death 
 
Following TBI, the cascade of excitotoxic damage leads to both cell death and damage 
to neighboring cells.  As a result of glutamate activation of the NMDA receptor, calcium 
enters the cell and accumulates in the mitochondria. The mitochondrial accumulation of 
calcium can lead to either necrotic or apoptotic cell death. Both cell death pathways can 
result in the further release of calcium which can perpetuate the process. 
 
 
 
linked to injury severity with moderately injured animals showing a 282% increase in 
glutamate and severely injured animals showing a 940% increase when compared to 
sham animals (Faden et al., 1989). Even though glutamate levels have been shown to 
increase after injury and be correlated with a worse outcome, simply showing post-injury 
increases in EAA levels is not sufficient to show that these changes directly play a role in 
increased pathology. To determine whether the increased levels of EAAs play a direct 
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role in outcome and pathology, various NMDA receptor antagonists have been utilized to 
prevent the activation of the NMDA receptor by glutamate (Faden et al., 1989, Shapira et 
al., 1990). Following a fluid percussion injury paradigm, administration of NDMA receptor 
antagonists have shown the ability to improve motor function and bioenergetic status 
(Faden et al., 1989) and reduce brain damage and edema (Shapira 1990). Even with the 
success of NMDA antagonists in animals models of TBI, attempts to move compounds 
into clinical usage has been met with much difficulty (for review see (Ikonomidou and 
Turski, 2002)). The usage of NMDA antagonists in humans has been linked to possible 
neurological damage (Davis et al., 2000) and animal models suggest NMDA antagonists 
may have a short and potentially unusable therapeutic window of efficacy in humans 
(Meldrum, 1990).  Even though the clinical usage NMDA antagonists to block 
excitotoxicity has not reached success as a treatment for brain injuries in humans, the 
mechanisms by which glutamate induced excitotoxicity leads to neuronal death is widely 
accepted. 
Mitochondrial permeability transition pore: 
 A downstream outcome from increases in mitochondrial calcium loading, such as 
from excitotoxicity, is the formation of the mitochondrial permeability transition pore 
(mPTP) (Sullivan et al., 2000c, Sullivan et al., 2005). The mPTP is a multi-protein 
complex which consists of the adenine nucleotide translocase (ANT), the voltage-
dependent anion channel (VDAC), and Cyclophilin D (Baines, 2009). The proteins which 
form the mPTP can be found both in the inner and outer mitochondrial membranes 
which allows for the efflux of substances from the IMS and matrix into the cytosol when 
the pore opens. Cytochrome C, endonuclease G, and apoptosis inducing factor (AIF) are 
three important substances released after the opening of the mPTP since their release 
from the mitochondria can lead to the activation of cell death cascades.  Endonuclease 
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G and AIF play an important role during apoptosis since they can initiate controlled DNA 
degradation. When Cytochrome C is released into the cytosol it is capable of interacting 
which the cytosolic protein Apaf-1 and form the apoptosome. The apoptosome recruits 
procaspase-9 and initiates the activation of caspases, such as Caspase-3, which drive 
the characteristic protein degradation observed with apoptosis. Therapeutic intervention 
with Cyclosporin A (CsA) can delay the opening of the mPTP and this intervention has 
been shown to have a beneficial effect in experimental models of TBI (Scheff and 
Sullivan, 1999, Sullivan et al., 1999c, Sullivan et al., 2000b, Sullivan et al., 2000c). 
Similar to excitotoxic mechanisms of cellular injury after TBI, intervening rapidly after a 
TBI in order to prevent the opening of the mPTP is critical to prevent the initiation the cell 
death cascades. 
Traumatic brain Injury induced changes in the dopaminergic system: 
 The dopaminergic (DA) neurons in the brain influence numerous functions 
including cognition, movement, and emotion (for reviews see (Jackson and Westlind-
Danielsson, 1994, Floresco and Magyar, 2006)). Dopamine neurons which originate in 
the substantia nigra (SN) send the majority of their projections into the striatum (ST) , 
however, axons also extend into the cortex and hippocampus as well (for review see 
(Van den Heuvel and Pasterkamp, 2008)). The DA fibers which project from the SN to 
the ST modulate the function of the basal ganglia (BG) by activating both D1 and D2 
dopamine receptors (Graybiel, 2000). The D1 and D2 receptors differ greatly in protein 
structure (Jackson and Westlind-Danielsson, 1994) and it is currently thought that 
activation of the D1 receptor serves to excite the direct pathway of the BG while 
activation of the D2 receptor functions to inhibit the indirect pathway (Graybiel, 2000). 
The summation of all of the interconnections within the BG culminates at the thalamus 
and results in a single refined signal being sent to the cortex. 
22 
 
 Following TBI, alterations in the DA system have been shown to occur and these 
changes are thought to underlie many of the deficits observed after TBI (for review see 
(Bales et al., 2009)). In humans, Donnemiller showed that following a severe TBI, where 
the average GCS was 5.8±4.2, patients exhibited alterations in both the dopamine 
transporter (DAT) and the D2 receptor (Donnemiller et al., 2000). Compared to controls, 
individuals which sustained a severe TBI had a loss of 55% of the DAT binding and 27% 
loss of D2R binding, however, the overall degree of change in Striatal DAT or D2R was 
not correlated with the severity of the TBI (Donnemiller et al., 2000). The lack of a direct 
correlation between TBI severity and the amount of change in the DA system indicates 
that even though TBI can produce DA deficits, since the GCS does not specifically 
measure DA function it cannot be used to predict the amount of DA dysfunction. Similar 
to what has been observed in humans, in a rodent model of severe TBI a 40% reduction 
in the levels of the DAT have been observed in the striatum 14 days after the injury 
(Wagner 2005). In these same animals, striatal evoked dopamine release was 
significantly reduced in injured animals ipsilateral to the injury and the Vmax for dopamine 
clearance was only 52.1% of naïve controls (Wagner et al., 2005). 
 Further evidence supporting a role for the DA system after TBI comes from the 
success of using the DA reuptake inhibitor methylphenidate as a treatment for cognitive 
and motor dysfunction after injury (Kaelin et al., 1996, Plenger et al., 1996, Whyte et al., 
1997). Plenger et al. showed in a double-blind placebo controlled study that at 30 days 
following subacute treatment with methylphenidate patients receiving the drug exhibited 
improvements in attention and motor function (Plenger et al., 1996). In another clinical 
trial, Whyte et al. showed that individuals who sustained a severe TBI showed significant 
improvements in information processing, attentiveness during individual work tasks, and 
caregiver ratings of attention (Whyte et al., 1997). Both of these reports only provided 
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indirect evidence of alterations in the DA system after TBI since the clinical trial studies 
only showed that the drug lead to improvements in function and not that there were 
deficits in DA system. It wasn’t until studies such as those conducted by Donnemiller et 
al. which showed changes in the DAT and D2R that evidence existed to show TBI 
dependent changes in the DA system. In order to elucidate how treatment with 
methylphenidate might be affecting function after TBI, Wagner et al. utilized a rodent 
model of severe TBI to look at the effects of methylphenidate on striatal dopamine 
function. After only a single injection of methylphenidate, injured animals did exhibit an 
increase in the amount of striatal evoked dopamine, however, the increase was not as 
high as what was observed in sham animals treated with a single dose of 
methylphenidate (Wagner et al., 2009), indicating that the injured brain responds 
differently to DA agonists. When the treatment regimen of methylphenidate was 
extended for two weeks, animals which received a severe TBI and treatment with 
methylphenidate exhibited both an increase in the total rate and amount of dopamine 
release in the striatum and these changes resulted in evoked dopamine levels similar to 
sham animals (Wagner et al., 2009). The results from the animal studies utilizing 
methylphenidate treatment after TBI show that injury does result in reductions in 
dopamine levels and that treatment with a DA agonist can reverse these changes if the 
drug is given long enough. Results from the animal studies further support what was 
observed in humans by Plenger et al. where stopping methylphenidate treatment 
resulted in the loss of a difference between drug and placebo  groups (Plenger et al., 
1996). When methylphenidate is allowed to wear off the increases in evoked dopamine 
release return to post-injury levels (Wagner et al., 2009). The human and rodent data 
suggest that following TBI the DA systems in the brain, especially in the striatum, 
become compromised and do not function adequately for normal function. Administration 
of a dopamine agonist, such as methylphenidate, is capable of overcoming some of the 
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deficits in the DA system and improving function, however, it does not lead to permanent 
changes. 
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Parkinson’s disease: 
Epidemiology: 
 Parkinson’s Disease (PD) is a neurodegenerative disorder characterized by the 
symptoms: tremor, rigidity, bradykinesia, hypokinesia, akinesia, and postural instability 
(Marsden, 1994), which result from the loss of dopaminergic (DA) neurons within the 
substantia nigra. PD generally affects individuals after age 65 and in the United States it 
is estimated that 60,000 new cases are diagnosed each year leading to a total of 1.5 
million people currently suffering with the neurological dysfunction which characterizes 
the disease. The motor impairment found in patients suffering with PD occurs in a 
progressive manner and worsens with time.  The loss of DA input into the striatum from 
the substantia nigra is the major neurological cause of the motor dysfunction (Marsden, 
1994) and human evidence suggests that loss of the majority of DA neurons in the 
substantia nigra must occur before motor dysfunction becomes apparent (Riederer and 
Wuketich, 1976, Morrish et al., 1996). Since Dr. James Parkinson first described the 
pathology of PD in his essay on “Shaking Palsy” (Parkinson, 2002), no definitive cause 
has been found which describes the etiology for all cases of sporadic PD.  
Anatomical circuitry of the basal ganglia: 
 The basal ganglia (BG) is a collection of brain nuclei which includes the striatum, 
globus pallidus, subthalamic nucleus (STN), and substantia nigra. The BG plays 
important roles in motor, associative, and limbic functions within the brain (Alexander et 
al., 1986, Middleton and Strick, 2000). DA projections from the substantia nigra 
innervate D1 and D2 receptors in the striatum and influence the interconnections 
between the remaining regions of the BG, which are interconnected by inhibitory 
GABAergic and excitatory glutamatergic fibers (Figure 1.5) (Graybiel, 2000) . The effect 
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of the BG circuitry on motor control is the most understood of its functions (Obeso et al., 
2008) and lesions in the STN and substantia nigra result in frequently characterized 
motor dysfunctions in humans. The arrangement of the neuronal connections within the 
BG are somatotopically organized (Takada et al., 1998) with the regions controlling 
motor function residing dorsolaterally (DeLong and Coyle, 1979). The substantia nigra 
impacts the function of the BG by exciting D1 neurons of the direct pathway and 
inhibiting D2 neurons from the indirect pathway (Figure 1.5) (Graybiel, 2000). The 
activities of the direct and indirect pathways result in the regulation of the amount of 
inhibition on the thalamus,  thereby modulating motor control through the thalamo-
cortical projections (Graybiel, 2000).  
Figure 1.5: Basal ganglia circuitry 
The normal circuitry of the basal ganglia (BG) involves interconnections between 
dopaminergic (DA), glutamatergic (Glu), and GABAergic (GABA) fibers. The regions of 
the BG are interconnected in such a 
way that allows for the control of 
thalamic activity and ultimately 
thalamic modulation of cortical 
function. In Parkinson's disease, the 
DA neurons in the substantia nigra 
are lost resulting in a loss of 
nigrastriatal DA input. The loss of 
nigral input into the striatum ultimately 
results in an increase in the inhibitory 
GABAergic single into the thalamus. 
The resulting inhibition of the 
thalamus leads to a decrease in the 
amount of input sent to the cortex 
from the thalamus which results in a 
decrease in motor output from the 
cortex. 
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Etiology: 
 Though much is known about the structure and function of the BG and its role in 
the development of PD, finding a single cause for the majority of idiopathic PD has 
remained elusive. Current evidence indicates that both genetic and environmental 
factors play an important role in the development of PD (for review see (Veldman et al., 
1998)). Genetic analysis utilizing twins has shown that for the majority of cases there is 
not a significant effect of genetics on the development of PD (Duvoisin et al., 1981, 
Marsden, 1987, Marttila et al., 1988), however, a rare mutation in the gene for α-
synuclein has shown that an autosomal dominant form of PD does exist (Golbe et al., 
1990, Golbe et al., 1996, Polymeropoulos et al., 1996). With the likelihood of developing 
PD solely because of a genetic mutation being low, the most likely causes for PD involve 
an  environmental component (Semchuk et al., 1993, Veldman et al., 1998). Exposure to 
toxins such a paraquat (Liou et al., 1997), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) (Langston et al., 1983), or TCE (Gash et al., 2008) have been shown to be 
linked to the development of PD in humans. Even with links between certain chemicals 
and the development of PD, a study looking a environmental causes of PD could not 
establish a link between the duration or level of exposure and disease development 
(Hertzman et al., 1994). The difficulty in establishing a human link between the level of 
chemical exposure and the development of PD is likely to be further complicated by the 
belief that PD arises from a multifactorial process (Carvey et al., 2006).  The premise of 
a multifactorial model for PD is that a single insult is insufficient to drive disease 
development and that the interaction of multiple insults results in a greater level of 
pathology. Considering the potential necessity for more than one insult opens the 
possibility that sub-pathological levels of single insults can interact and either additively 
or synergistically lead to pathology.  
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Traumatic brain injury is another factor which has been linked to the development 
of PD and could interact in a multifactorial mechanism. Bower et al. showed that 
individuals which experienced either a TBI which resulted in a loss of consciousness or a 
severe TBI had an increased risk of developing PD later in life (Bower et al., 2003) and 
TBI was shown in a separate study to be the second most likely cause of PD in humans 
(Semchuk et al., 1993). TBI has been shown to produce alterations in the striatum which 
are similar to PD (Donnemiller et al., 2000) and experimental studies have shown that 
following a severe TBI there are deficits in the striatal DA system (Wagner et al., 2005). 
The link between TBI and PD likely involves both direct and multifactorial mechanisms. 
Human and experimental research indicates that, independently of other insults, TBI can 
damage the BG and produce alterations similar to what has been observed in human PD 
patients. If an individual who experiences a TBI is also exposed to an environmental 
toxin it could be expected that the pathological outcome would be more severe. 
 A common factor between PD, TBI, and toxins linked to PD is the involvement of 
mitochondrial dysfunction (Ramsay et al., 1986, Vyas et al., 1986, Schapira et al., 1990, 
Sullivan et al., 1998b, Sullivan et al., 1999c, Sherer et al., 2003, Lifshitz et al., 2004, 
Bender et al., 2006). The environmental pollutant TCE (Gash et al., 2008, Liu et al., 
2010), the pesticide rotenone (Sherer et al., 2003), and the toxin MPTP (Nakamura et 
al., 2000) have all been shown to produce mitochondrial dysfunction in the brain and are 
linked to the development of PD. Mitochondrial dysfunction has been further linked to the 
development of PD since two treatments which act at the mitochondrial level, CoQ10 
(Shults et al., 2002) and creatine (Matthews et al., 1999), have shown promise in 
treating disease symptoms in preclinical studies. The mechanisms by which 
mitochondrial toxins lead to PD involve impairment of mitochondrial bioenergetic function 
through the inhibition of mitochondrial respiration. By blocking the function of the 
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electron transport chain, inhibitors lead to reductions in ATP levels and increases in 
damaging ROS, both of which can lead to cell death (Chen et al., 2007b). In addition to 
toxin induced mitochondrial dysfunction, genetic mutations in several genes encoding 
mitochondrial proteins have also been linked to the development of PD. Mutations in DJ-
1 (Bonifati et al., 2003), Pink1 (Valente et al., 2004), and Parkin (Kitada et al., 1998) 
have all been linked to PD in human studies and the mechanisms of pathology involve 
mitochondrial components (for review see (Cho et al., 2010).  
The link between genetic mutations in mitochondrial proteins further supports the 
role of a multifactorial mechanism since studies utilizing the toxin 6-hydroxydopamine 
have shown a requirement for specific mitochondrial proteins in order to develop 
pathology (Gomez-Lazaro et al., 2008). The evidence from human and experimental 
studies strongly supports the notion that there are many factors which can play a role in 
the development of PD. Few cases exist that show a clear single insult mechanism of 
disease development and that alone supports the concept of multi-insult pathway for 
developing PD. The interactions between genetics and environmental insults likely drive 
the loss of the DA neurons in the substantia nigra and lead to the classical histological 
and motor impairments of PD. 
Trichloroethylene:  
 Trichloroethylene (TCE), C2HCl3, is a halogenated hydrocarbon that has been 
widely used as a solvent in the United States for degreasing, dry cleaning, food 
processing, paint production, and as an anesthetic (EOHS, Bakke et al., 2007). It is 
estimated that as of 1997 over 400,000 workers were annually exposed to TCE in the 
workplace (ATSDR, 1997). TCE has been detected at 861 National Priorities List 
hazardous waste sites, with 213 of these sites having completed exposure pathways  
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Figure 1.6: Trichloroethylene structure and environmental exposure 
 
 
 
   
Trichloroethylene consists of a carbon-carbon double bond which is attached to three 
chloride ions. As of 1997, 861 National Priorities List toxic sites were contaminated with 
TCE and of these, 213 also had complete exposure pathways which resulted in the 
contamination of ground water systems and the potential exposure of the communities 
around the site. The number of toxic sites containing TCE can vary widely between 
states, however, every state which had data available contained at least one location 
contaminated by TCE. (n.d. = no data provided, figure edited from ATSDR, 1997) 
 
 
allowing TCE to reach the population in proximity to the site (Figure 1.6) (ATSDR, 1997). 
Acute exposure to TCE can lead to narcotic symptoms and chronic exposure can lead to 
encephalopathy, polyneuropathy, trigeminal affection, and hearing loss (EOHS). 
Following exposure to TCE, deficits including memory impairment, sensorimotor 
neuropathy, facial muscle twitching, and decreased facial sensation have been shown to 
persist for years (Feldman et al., 1985). Kilburn conducted an age matched study of 
people exposed to TCE by inhalation and well water and found that exposed individuals 
exhibited significant deficits in reaction time, balance, blink responses, cognitive 
function, and motor speed as compared to regional referents (Kilburn, 2002). Similar to 
the finds of Kilburn, Gash et al. observed that in factory workers chronically exposed to 
TCE for many years that exposure was linked to the development movement 
impairments (Gash et al., 2008). Strikingly, the findings by Gash showed a link between 
31 
 
the level of exposure to TCE and the development of pathology since individuals which 
were directly working with the TCE developed worse symptoms than individuals which 
worked more distantly and therefore exposed to lower levels of TCE by inhalation (Gash 
et al., 2008). 
 Given the link between mitochondrial dysfunction and PD (Schapira et al., 1989) 
and the evidence that TCE exposure can lead to PD (Kilburn, 2002, Gash et al., 2008), 
rodent experiments sought to further elucidate the connection between TCE and PD 
(Gash et al., 2008, Liu et al., 2010). Rats which were exposed to TCE for six weeks 
exhibited significant mitochondrial bioenergetic impairment, a loss of tyrosine 
hydroxylase positive neurons in the SN, and changes in dopamine turnover kinetics in 
the striatum (Gash et al., 2008). Further analysis of the effects of TCE on the brain 
revealed that exposure led to increases in mitochondrial oxidative damage, 
accumulation of α-synuclein both in the SN and the dorsal motor nucleus of the vagus, 
and motor impairment (Liu et al., 2010). The results from the animal studies support 
what has been observed in humans exposed to TCE since experimental exposure to 
TCE resulted in symptoms of PD including motor impairment. 
 It was hypothesized by Bringmann that the downstream metabolite of TCE, 1-
trichloromethyl-1,2,3,4-tetrahyro-β-carboline (TaClo), may be the component of TCE 
exposure responsible for the deficits. TaClo has been shown in in vitro models to 
significantly inhibit Complex I of the mitochondrial respiratory chain (Janetzky et al., 
1995) and induce apoptosis through the release of mitochondrial Cytochrome C (Akundi 
et al., 2004). With the availability of both experimental (Grote et al., 1995, Janetzky et 
al., 1995, Akundi et al., 2004) and clinical reports (Guehl et al., 1999, Kochen et al., 
2003) of mitochondrial and dopaminergic toxicity following exposure to either TCE or its 
metabolite TaClo, evidence has accumulated to implicate TCE (Kochen et al., 2003) and 
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TaClo (Bringmann et al., 1995b, Riederer et al., 2002) as relevant neurotoxins in the 
development of PD. It has been shown that exposure to an environmental factor long 
before the onset of symptoms of PD correlates with the future development of pathology 
(Veldman et al., 1998, Brown et al., 2005, Landrigan et al., 2005) and this may be the 
result of either a slow continuous neuronal decline or a predisposition towards increased 
susceptibility to future insults. 
 
Multifactorial pathogenesis of Parkinson’s disease: 
 The search for a single causative factor responsible for the development of PD in 
humans has been a major difficultly in understanding the pathogenesis of the disease. 
Causative factors such as exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) (Langston et al., 1983) or familial genetic mutations in the gene encoding α-
synuclein (Golbe et al., 1990, Golbe et al., 1996, Polymeropoulos et al., 1996) have 
been shown to independently result in pathology, however, these factors are not likely to 
be the cause for most cases of idiopathic sporadic PD. With the difficulty finding single 
insults which can independently produce models PD that involve a progressive loss of 
dopamine neurons, attention has been given to the concept of a multifactorial 
mechanism (Veldman et al., 1998, Carvey et al., 2006).  Age is considered to be a major 
factor in the development of PD and after age 50 up to 6% of dopamine neurons in the 
substantia nigra are lost (Gibb and Lees, 1991). Given that the normal loss of nigral cells 
is thought to be insufficient to independently produce functional impairment (McGeer et 
al., 1977, Kish et al., 1992), Carvey proposed the idea that the combination of age and a 
second insult may be required to drive disease development (Carvey et al., 2006). Given 
that age is linked with the development of PD but the normal loss of nigral neurons is 
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less than typically needed for functional impairment, a combination of genetics, 
environmental factors such as herbicides, pesticides, and head trauma may be needed 
to interact over the course of an individual’s lifetime to lead to pathology (for review see 
(Veldman et al., 1998)). 
 Multifactorial experiments have shown that neurons can be made more 
susceptible to future insults following exposure to a toxin (Arundine et al., 2004, Ling et 
al., 2004b). Numerous studies show that a variety of dual injuries can produce increased 
pathology in animal models of PD (Thiruchelvam et al., 2000a, Thiruchelvam et al., 
2000b, Arundine et al., 2003, Arundine et al., 2004, Ling et al., 2006, Fei and Ethell, 
2008) and these represent potential scenarios for how human PD develops. Exposure 
the herbicide Paraquat has been linked to an increased risk of PD development (Liou et 
al., 1997), however, other reports indicate there is not a direct link between Paraquat 
and PD (Koller, 1986). Exposure to another insult in addition to Paraquat exposure may 
be the necessary link which allows some studies to find a link to PD development while 
other studies do not. Thiruchelvam et al. showed that exposure the pesticide Maneb in 
addition to Paraquat exposure produced even greater deficits to the DA system in animal 
models (Thiruchelvam et al., 2000a, Thiruchelvam et al., 2000b, Thiruchelvam et al., 
2002). Combining age with toxin exposure revealed that older animals are more 
susceptible to exposure to either Paraquat or Maneb alone and that the combination of 
age, Paraquat exposure, and Maneb exposure produced the greatest deficits to the 
dopaminergic system (Thiruchelvam et al., 2003).  
In addition to insults which individuals experience as adults, it is also thought that 
childhood insults may play a role in the development of PD later in life (Martyn and 
Osmond, 1995). Rural living has been linked to the development of PD (Rajput et al., 
1986, Rajput et al., 1987) and decreased numbers of nigral dopamine neurons 
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(Thiessen et al., 1990) and this may represent early life exposure to environmental 
factors which caused these differences. In addition to rural living, exposures in utero, 
such as from maternal bacterial infections, may play a role in disease development. In 
an experimental prenatal exposure model,  it has been shown that prenatal exposure to 
the bacteriotoxin lipopolysaccharide (LPS) results in a decrease in the number of DA 
neurons at birth (Ling et al., 2002) and that when the prenatal exposure is combined with 
postnatal toxin exposure the loss of DA neurons is even more pronounced (Ling et al., 
2004a, Ling et al., 2004b). Whether toxin exposure occurs during development or after 
birth, there is clear evidence that the combination of exposure to multiple toxins can 
result in greater deficits in the DA system. 
  
Peroxisome proliferator activator receptors: 
PPARs in normal cellular function: 
 The peroxisome proliferator-activated receptors (PPARs) are members of the 
nuclear receptor superfamily and regulate gene expression using various ligand-
dependent and independent molecular processes. Three isoforms of the PPARs exist: 
PPARα, PPARγ, and PPARδ, and each isoform is the product of a separate gene 
(Dreyer et al., 1992, Michalik and Wahli, 1999, Torra et al., 2001). While these isoforms 
have similar protein sequence and structure, they differ in their ligand-binding domains 
and have different ligand specificity, tissue distribution, and biological actions (Guan et 
al., 2002). PPARs regulate the expression of their respective target genes through the 
interaction with 9-cis retinoic acid receptors and the formation of heterodimers (Kliewer 
et al., 1992). Defects in PPAR genes do not result in major changes to basal function, 
however, these changes lead to alterations in the ability to activate the PPAR receptors. 
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Fatty acids and prostaglandins serve as endogenous activators of the PPAR system 
under normal conditions (Forman et al., 1997, Kliewer et al., 1997, Berger et al., 2005) 
and exogenously fibric acids and thiazolidinediones (TZDs) have been utilized as 
pharmaceutical ligands (Forman et al., 1995, Lehmann et al., 1995, Forman et al., 
1997). Under normal physiological conditions PPARα and PPARγ function to control lipid 
and glucose metabolism respectively (Berger et al., 2005). The pathways interact in 
various ways such as the ability of PPARγ to initiate the storage of lipids (Debril et al., 
2001) and PPARα to control lipid metabolism. 
 Under injury conditions PPAR activation has been shown to modulate 
inflammatory responses. The most common method utilized by PPARs to regulate gene 
expression is through transrepression (Moraes et al., 2006). PPARs have been shown to 
significantly modulate inflammatory processes through the regulation of genes such as 
nuclear factor-kappa B (NFκB), activator protein-1 (AP-1), signal transducer and 
activator of transcription (STAT), and nuclear factor of activated T cells (NFAT) (Ricote 
et al., 1998, Delerive et al., 2001, Park et al., 2003, Bernardo and Minghetti, 2006). The 
regulation of these genes allows the PPAR system to affect macrophages, microglia, 
dendritic cells, endothelial cells, B cells, and T cells (Clark, 2002, Daynes and Jones, 
2002, Hunter, 2007)). Inflammation and oxidative stress have been shown to play an 
important role in cell death after injury (Andersen, 2004) and given the ability for PPARs 
to regulate proteins such as NFκB, it has been proposed that they will be effective in 
various neurological disorders (Feinstein, 2003). 
PPARs in CNS disorders: 
  The PPARγ agonists Pioglitazone and Rosiglitazone are both FDA approved 
drugs for diabetes treatment (for review see (Sood et al., 2000) and have been utilized 
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as therapeutics in animal models of CNS injury (Besson et al., 2005, Kiaei et al., 2005, 
Schutz et al., 2005, Collino et al., 2006, Chen et al., 2007a, McTigue et al., 2007, Park et 
al., 2007, Chen et al., 2008, Feng et al., 2008, Hyong et al., 2008, Sun et al., 2008, Yi et 
al., 2008, Allahtavakoli et al., 2009). Rosiglitazone has been previously shown to have a 
higher binding affinity for the PPARγ receptor (Young et al., 1998), however, 
Pioglitazone has been shown to more readily cross the blood brain barrier (BBB) (Berger 
and Moller, 2002) as well as partially activate the PPARα receptor (Sakamoto et al., 
2000). Currently evidence exists showing that activation of either the PPARα (Chen et 
al., 2007a, Chen et al., 2008) or PPARγ (Yi et al., 2008) pathways are protective in 
models of TBI. However, given Pioglitazone’s increased brain penetration and activation 
of two separate PPAR pathways it may yield a greater therapeutic potential for the 
treatment of TBI ( for review see (Kapadia et al., 2008).  
 Treatment with the PPARγ agonist Pioglitazone following lipopolysaccharide 
(LPS) induced brain inflammation has shown the ability to prevent both mitochondrial 
impairment and neuronal cell loss (Hunter et al., 2007). The therapeutic use of various 
PPARs has shown benefit in multiple CNS injury models including spinal cord injury 
(SCI) (McTigue et al., 2007, Park et al., 2007), TBI (Besson et al., 2005, Chen et al., 
2007a, Chen et al., 2008, Yi et al., 2008), and stroke (Collino et al., 2006, Allahtavakoli 
et al., 2009). Of the three known PPAR isoforms, PPARα and PPARγ have been the 
most well studied in CNS injury and have been shown to reduce lesion size both in SCI 
(McTigue et al., 2007, Park et al., 2007) and TBI (Yi et al., 2008), reduce inflammation 
(Besson et al., 2005, Chen et al., 2007a, Park et al., 2007, Hyong et al., 2008, Kapadia 
et al., 2008), minimize oxidative damage (Chen et al., 2007a, Yi et al., 2008), spare 
neurons (McTigue et al., 2007, Park et al., 2007), and preserve behavioral function 
(Chen et al., 2007a, McTigue et al., 2007, Park et al., 2007, Chen et al., 2008). In 
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addition to the anti-inflammatory properties of PPAR ligands, treatment with PPAR 
agonists have also been shown to protect neuronal vasculature after an ischemic insult 
(Inoue et al., 2003). The protective effects of PPARs on the vasculature after injury has 
been shown to involve the prevention of increases in matrix-metalloproteinase-9 along 
with increasing levels of the protective protein Hemeoxygenease-1 (Pereira et al., 2005). 
Along with traumatic and acute injuries, PPAR ligands have shown effectiveness in 
experimental models of PD (Breidert et al., 2002). Following administration of the toxin 
MPTP, treatment with the PPARγ ligand Pioglitazone resulted in reductions in glial 
activation and cell loss in the substantia nigra (Breidert et al., 2002) as a result of 
increases in IκBα and reductions in NFκB (Dehmer et al., 2004). PPAR activation has 
been shown to be protective in other neurological disorders such as Alzheimers disease 
(Heneka et al., 2005) and multiple sclerosis (Feinstein et al., 2002, Lovett-Racke et al., 
2004) through similar mechanistic processes. It is most likely the neuroprotective effects 
afforded by treatment with PPAR agonists involve a pleotropic process whereby 
activation of the PPAR system affects multiple pathways. 
Summary: 
A common aspect of many of the toxins linked to the development of PD is that 
they can inhibit mitochondrial bioenergetic function. The maintenance of mitochondrial 
function is critical to preventing cell death since neuronal ATP stores can be depleted 
within minutes and lead to the initiation of cell death pathways (Nilsson, 2001). A toxin 
which is capable of inhibiting the mitochondrial respiratory chain such as MPTP 
(Ramsay et al., 1986, Vyas et al., 1986), rotenone (Sherer et al., 2003), TCE (Gash et 
al., 2008, Liu et al., 2010), or TaClo (Janetzky et al., 1995), could produce a chronic 
decrease in ATP levels making neurons more susceptible to future insults since the cell 
would already be in a compromised state from energy depletion. Similar to the toxin 
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exposure models showing increased loss of dopamine neurons after exposure to two 
different toxins, the combination of mitochondrial inhibition and a second insult have the 
potential to interact and produce greater pathology.  
Head trauma has also been linked to the development of PD (Semchuk et al., 
1993, Bower et al., 2003) however it has not been shown to be independently causative 
for the development of PD (Factor et al., 1988). Though it remains yet to be proven, the 
ability for trauma to drive PD may involve other factors or insults to be on going (Koller et 
al., 1989). Currently there is no complete understanding of how idiopathic sporadic PD 
develops in humans. A likely scenario is that multiple environmental and genetic factors 
exist which can potentiate disease development but that under most conditions human 
exposure to only one factor is not sufficient to independently cause PD and therefore a 
multifactorial insult is more capable of producing PD.  
With the ability of TCE to affect mitochondrial function (Gash et al., 2008), it is 
possible that exposure prior to a TBI may lead to a worse outcome. Additionally, regional 
differences in mitochondrial function and/or the susceptibility to mitochondrial inhibition 
may affect to development of pathology following toxin exposure and how the interaction 
between the toxin and TBI occurs. Given the role TBI may play in a dual injury process, 
and the impact TBI has as an individual condition, finding effective therapeutic 
interventions will likely help in ameliorating both of these issues. 
 
 
 
Copyright © Andrew David Sauerbeck 2011 
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Chapter 2 
Traumatic brain injury and trichloroethylene exposure interact and produce 
functional, histological, and mitochondrial deficits. 
 
 
Introduction: 
One of the pivotal, common pathways shared between traumatic brain injury 
(TBI), toxin induced neurodegeneration, and Parkinson’s disease (PD) is the disruption 
of normal mitochondrial function (Ramsay et al., 1986, Vyas et al., 1986, Schapira et al., 
1990, Sullivan et al., 1998a, Sullivan et al., 1999c, Sherer et al., 2003, Lifshitz et al., 
2004, Bender et al., 2006). To date, research has shown that these three insults may be 
able to interact at the mitochondrial level. Given the similar changes in mitochondrial 
function observed with these pathologies, exposure to a mitochondrial toxin prior to a 
TBI is hypothesized to produce a multifactorial injury with pathological changes greater 
than either insult alone. 
Exposure to an environmental factor long before the onset of symptoms of PD 
has been shown to correlate with the future development of pathology (Veldman et al., 
1998, Brown et al., 2005, Landrigan et al., 2005) and this may be the result of either a 
slow continuous neuronal decline or a predisposition towards increased susceptibility to 
future insults such as TBI. One such factor environmental factor which has been linked 
to PD is trichloroethylene (TCE), C2HCl3. TCE is a halogenated hydrocarbon carbon that 
has been widely used as a solvent in the United States for degreasing, dry cleaning, 
food processing, paint production, and as an anesthetic (EOHS, Bakke et al., 2007). It is 
estimated that as of 1997 over 400,000 workers were annually exposed to TCE in the 
workplace (ATSDR, 1997). TCE has been detected at 861 National Priorities List 
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hazardous waste sites, with 213 of these sites having completed exposure pathways 
allowing TCE to reach the population in proximity to the site (ATSDR, 1997). Exposure 
to TCE has been shown to cause mitochondrial dysfunction (Gash et al., 2008) and a 
loss of dopaminergic neurons in the substantia nigra (Liu et al., 2010). The downstream 
metabolite of TCE, 1-trichloromethyl-1,2,3,4-tetrahyro-β-carboline (TaClo), has been 
shown to inhibit Complex I of the mitochondrial respiratory chain (Janetzky et al., 1995) 
and induce apoptosis through the release of mitochondrial Cytochrome C (Akundi et al., 
2004). With the availability of both experimental and clinical reports of mitochondrial and 
dopaminergic toxicity following exposure to either TCE or its metabolite TaClo, evidence 
has accumulated to implicate TCE (Kochen et al., 2003, Gash et al., 2008, Liu et al., 
2010) and TaClo (Bringmann et al., 1995b, Riederer et al., 2002) as relevant neurotoxins 
in the development of PD.  
The development of PD has been linked to TBI both in epidemiological studies 
(Factor and Weiner, 1991, Stern, 1991, Semchuk et al., 1993, Taylor et al., 1999, Bower 
et al., 2003) and in clinical evaluations (Nayernouri, 1985, Doder et al., 1999). Patients 
sustaining a mild head trauma with a loss of consciousness or a severe head trauma 
have a significant increase in the probability of developing PD later in life (Bower et al., 
2003). Although there have been multiple reports linking TBI to PD (Factor and Weiner, 
1991, Stern, 1991, Semchuk et al., 1993, Bower et al., 2003), current evidence only 
shows TBI to be a risk factor and has failed to show a causative link (Factor et al., 1988). 
The disruption of mitochondrial function and the initiation of cell death mechanisms may 
play a direct role linking TBI and PD. Mitochondrial dysfunction after TBI can result in 
reductions in ATP levels (Sullivan et al., 1998a), increases in lipid peroxidation (Sullivan 
et al., 1998a), release of Cytochrome C and activation of apoptotic pathways (Sullivan et 
al., 2002), resulting in cell death. The role of the mitochondria is critical after TBI since it 
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is capable of functioning as a regulator of cell death mechanisms and these changes 
likely worsen an individual’s outcome from an additional insult. 
Given the numerous factors linked to PD, including TCE and TBI, the concept 
that the development of PD involves a multifactorial injury has emerged (Semchuk et al., 
1993). Multifactorial experiments have shown that neurons can be made more 
susceptible to future insults following exposure to a toxin (Arundine et al., 2004, Ling et 
al., 2004b). A toxin, such as TCE, which is capable of inhibiting the mitochondrial 
respiratory chain (Gash et al., 2008), could make neurons more susceptible to future 
insults. The chronic inhibition of Complex I by TCE and a resulting decline in energy 
stores may be the link allowing TCE and TBI to interact. Based on previous studies 
showing dual injuries can produce increased pathology (Thiruchelvam et al., 2000a, 
Thiruchelvam et al., 2000b, Arundine et al., 2003, Arundine et al., 2004, Ling et al., 
2006, Fei and Ethell, 2008), we sought to test the hypothesis that TCE exposure and TBI 
can interact to produce a greater level of disease pathology. This is the first report of 
these two insults being studied together and provides further support that sporadic PD 
may be the result of a multifactorial process. 
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Methods: 
 
 All studies were approved by the University of Kentucky Institutional Animal Care 
and Usage Committee and utilized male Fischer 344 rats 16 weeks old (Harlan 
Laboratory). Animals were housed in groups of three per cage with food provided ad 
libitum and 12-hour light/dark cycles. For the first set of studies there were six treatment 
groups which consisted of animals which were exposed to trichloroethylene or vehicle 
followed by either a sham, mild (1.0mm), or moderate (2.0mm) brain injury. For lesion 
volume and mitochondrial studies the mild (1.0mm) group was not generated. A total of 
156 animals were utilized for the completion of these studies.  
 
Trichloroethylene treatment and controlled cortical impact brain injury: 
  Animals were orally gavaged 0.6ml of either the olive oil vehicle (Kroger Pure 
Olive Oil) or 1000mg/kg trichloroethylene (Sigma Aldrich) daily for either 1 week or 2 
weeks using a 100mm gavage needle (Fine Science Tools) with a 16 gauge tip sized to 
prevent insertion of the needle into the trachea. The health of the animals was monitored 
during the entire duration of the experiments to ensure no animals became morbidly 
sick. Following treatment with trichloroethylene, animals received either a sham brain 
injury or a controlled cortical impact brain injury using previously established methods 
(Sullivan et al., 1998b, Sullivan et al., 1999c, Sullivan et al., 2000c).  Animals were 
anesthetized with 2% isofluorane and placed in a Kopf stereotaxic frame for positioning 
under a pneumatic impactor (Precision Science Instruments). A 6 mm craniotomy was 
performed, with a hand trephine, lateral to the central fissure on the left side of the skull 
centered between lambda and bregma. Animals in injury groups received a unilateral 
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injury directly to the surface of the brain. The injury parameters consisted of a 1.0mm 
deep impact for mild injured animals and a 2.0 mm deep impact for moderate injured 
animals at 3.5 meters/second for 500ms. Sham animals received a craniotomy but did 
not receive an impact to the brain. Following the injury a piece of Surgicel 
(Johnson&Johnson) sized to fit into the craniotomy was placed directly on the brain. The 
skull cap was replaced and secured in place with dental acrylic. Once the acrylic was 
allowed time to harden, the scalp incision was closed with surgical staples. Animals were 
removed from isofluorane and placed in a clean cage and body temperature was 
maintained at 37oC with the use of a heating pad. Five to six animals per group were 
utilized throughout all of the experiments. Following the brain injuries, animals were 
housed in their home cages until post-injury behavioral analysis was begun. 
 
Behavioral analysis:  
Rotarod testing: Nine days after the brain injury surgeries Rotarod testing was 
begun for all treatment groups. Animals were trained on a Rotarod (Med Associates Inc.) 
for three days at speeds of 8rpm, 12rpm, and then 16rpm. On the fourth day (12 days 
post TBI) animals were tested on the Rotarod using an accelerating speed starting at 
3rpm and holding at 30rpm. The time animals were able to stay on the Rotarod on the 
fourth day was determined by a timer built into the Rotarod which was stopped when the 
animal fell off the Rotarod and blocked an infrared light sensor. Animals were tested 
twice on the fourth day and the times for each trial were averaged for each animal.  
Cylinder testing: Thirty days after the brain injury, animals underwent cylinder 
testing to access alterations in paw placement. Animals were placed in a clear plastic 
cylinder with a diameter of 19cm which was mounted on a plexiglass surface with an 
angled mirror underneath to allow video recording of the animals for 5min. Video 
recordings were performed using a digital video camera, and the footage was analyzed 
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using QuickTime software (Apple Computer Inc.) with playback set at ½ actual speed. 
The number of contralateral and ipsilateral paw touches was quantified blinded to 
treatment group. The percentage of contralateral forepaw usage was calculated using 
the formula  . 
 
Histological analysis:  
 Following the completion of the cylinder testing, animals were sacrificed for post 
injury histological analysis. Animals were anesthetized with sodium pentobarbital (Abbot 
Laboratories) and transcardially perfused with saline followed by 4% paraformaldehyde. 
The brains were removed and placed in 4% paraformaldehyde and 30% sucrose in PBS 
for 24hrs. After 24hrs the brains were transferred to a 30% sucrose PBS buffer without 
paraformaldehyde. Coronal sections 30µm thick were cut with a freezing microtome 
throughout the rostral caudal extent of the entire brain.  Nissl staining was performed to 
visualize the intact regions of the cortex for cortical tissue sparing analysis. Quantitative 
assessment of cortical damage employed an unbiased protocol using the Cavalieri 
method as previously described (Sullivan et al., 2000c, Sullivan et al., 2002).  All slides 
were assessed blindly with respect to treatment group. For immunohistochemistry, 
sections containing regions of interest were incubated overnight at 4°C with a primary 
antibody.  Slices were stained for tyrosine hydroxylase using a primary monoclonal 
antibody (Chemicom) followed by a biotinylated anti-mouse secondary antibody (Vector). 
Following the secondary antibody treatment sections were treated with an Avidin Biotin 
Peroxidase Complex, Vectastatin ABC Kit (Vector). The tissue was developed with a 
diaminobenzidine tetrahydrochloride (DAB) solution with nickel intensification to allow 
stable long term staining and visualization with a light microscope. Bioquant Image 
Analysis software (Bioquant, Nashville, TN) was used to estimate total cell number in the 
45 
 
region of interest using the optical fractionator method (Mouton, 2002). This method 
represents an unbiased quantitative technique that is independent of size and shape or 
any conformational changes of cells.  Detailed procedures regarding stereological 
counting  are similar to our previously published studies (Liu et al., 2008). Coronal 
sections containing the substantia nigra (interaural 2.7-4.2) (Paxinos and Watson, 1998) 
were used to estimate the total number of tyrosine hydroxylase (TH) positive cells in the 
SN.  A set of 6 systematic sections were sampled in an independent-random manner 
from a total of 36-39 sections containing the entire reference space. On each stained 
section the area containing the SN was identified using conventional landmarks 
(Paxinos, 2004). An unbiased grid was overlayed on each section and a random number 
system embedded in the software used to identify areas of the grid for counting. On 
each identified grid position an unbiased counting frame was used for the optical 
dissector. The counting frame was 150 X 150μm centered on the grid intersection. The 
height of each dissector was determined with a digital z-axis encoder (Boeckeler 
Instruments, Tucson, AZ).  Cells were identified using a 40X objective with a high 
numerical aperture. The total number of cells (N) was estimated using the formula  N = 
Q • 1/hsf • 1/asf • 1/ssf where Q is the total number of cells actually counted, hsf is the 
height sampling fraction, asf is the area sampling fraction, and ssf is the section 
sampling fraction.  Image Pro software was used for the quantification of the area of the 
striatum immunoreactive for TH in a blinded fashion. High resolution images throughout 
the entire striatum stained for TH were taken using an Olympus AX80 microscope. Using 
Image Pro, the perimeter of the striatum was outlined and the percentage area which 
was immunoreactive for TH was calculated. The average amount of immunoreactivity for 
a single animal was calculated separately for both the ipsilateral and contralateral sides 
of the brain. 
 
46 
 
Western blot analysis:  
Quantification of dopamine transporter and receptor levels in the striatum was 
performed using standardized western blot protocols. Animals were asphyxiated with 
CO2 and rapidly decapitated. The striatum was rapidly dissected, placed into plastic 
tubes, and the tubes were placed into a bath of dry ice and ethanol to rapidly freeze the 
tissue. Samples were frozen at -80oC until homogenized. At the time of homogenization 
samples were placed into lysis buffer (0.1M NaCl, 0.01M Tris-Cl, 0.001 EDTA, 1ug/ml 
aprotinin, 100ug/ml phenylmethylsulfonyl fluoride) and homogenized using low intensity 
sonication for 30 seconds. Samples were centrifuged at 13,800xG for 30min at 4oC. The 
protein concentrations were determined with all the samples on the same plate using the 
BCA protein assay kit and measuring absorbance at 560nm with a Biotek Synergy HT 
plate reader (Winooski, Vermont). Protein separation was performed using a 4% 
stacking gel followed by a 10% separation gel. Gels were run for one hour at 150 volts 
and 4oC with constant stirring. Following gel separation, proteins were transferred to 
nitrocellulose utilizing a wet transfer setup at 100 volts for one hour. Following protein 
transfer to the nitrocellulose, blots were washed three times with TBS and blocked with 
5% milk in TBS for one hour at room temperature. After blocking, blots were washed 
three times with TTBS at room temperature with constant agitation. Primary antibodies 
towards the proteins of interest were prepared in 5% milk in TTBS. For quantification of 
the dopamine transporter, 40ug of protein was loaded per well and the primary antibody 
(Millipore) was applied at a concentration of 1:1500 and incubated overnight. For 
quantification of the dopamine receptor, 60ug of protein was loaded to the gel and the 
primary antibody (Santa Cruz) was applied at a concentration of 1:800 and incubated 
overnight. Following incubation with the primary antibody, blots were washed with TTBS 
and incubated with an infrared secondary antibody (Rockland) at a concentration of 
1:5000. Band intensities were determined using a Licor Odyssey infrared imager. Levels 
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of each protein were expressed as a ratio of the protein of interest compared to the 
amount of actin for the same sample. Six animals per group were utilized for western 
blot analysis. 
 
Mitochondrial isolation and oxygen consumption analysis:   
 Mitochondria from the striatum and substantia nigra were isolated using 
differential centrifugation, nitrogen disruption, and a Ficoll gradient. Animals were 
asphyxiated with CO2 and rapidly decapitated. Dissected tissue was removed and 
immediately placed in ice-cold isolation buffer (215mM Mannitol, 75mM Sucrose, 0.1% 
BSA, 1mM EGTA, and 20mM Hepes at pH 7.2). Due to the small size of the substantia 
nigra, three animals were combined for each mitochondrial sample, resulting in an n=1 
for these three animals. Samples were homogenized and centrifuged at 1300xG for 3 
minutes. Following the first spin the supernatant was placed in a fresh tube and the 
pellet was resuspended in isolation buffer and spun at 1300xG for 3min. The 
supernatant from the first and second spins were collected in separate tubes and spun 
at 13,000rcf for 10 minutes. The pellets from both tubes were combined, resuspended in 
400ul isolation buffer and placed in a nitrogen bomb at 1,200psi for 10min. The pressure 
in the nitrogen bomb was rapidly released and the sample was placed as the top layer 
on a Ficoll separation column which consisted of a 10% Ficoll layer and a 7.5% Ficoll 
layer. The Ficoll column with sample was centrifuged at 100,00xG for 30min at 4oC using 
a Beckman SW 55Ti rotor and ultra-centrifuge. The final mitochondrial pellet was 
resuspended in isolation buffer without EGTA to yield a final concentration of 
approximately 10mg/ml, and stored immediately on ice. To normalize the results, the 
protein concentrations were determined with all the samples on the same plate using the 
BCA protein assay kit and measuring absorbance at 560nm with a Biotek Synergy HT 
plate reader (Winooski, Vermont). Following two week exposure to TCE, mitochondrial 
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oxygen consumption was measured using a Clark-type electrode (Hansatech 
Instruments, Norfolk, England) in a continuously stirred, sealed chamber at 37°C as 
previously described (Sullivan et al., 2003). Isolated mitochondrial protein (100µg) was 
suspended in respiration buffer (215 mM mannitol, 75 mM sucrose, 0.1% BSA, 20 mM 
HEPES, 2 mM MgCl, 2.5 mM KH2PO4 at pH 7.2) in a final chamber volume of 0.25 mL. 
Mitochondrial bioenergetic analysis was measured by the sequential administration of 
substrates: 5mM Pyruvate, 2.5mM Malate, 150nM ADP, 1uM Oligomycin, and 1uM 
FCCP. Five to six animals per groups were utilized for all of the mitochondrial studies. 
 
Seahorse protocol for isolated mitochondria: 
Experiments utilizing 1 week exposure to TCE were performed with the Seahorse 
Biosciences XF24 for analysis of mitochondrial oxygen consumption. The following 
protocol was utilized for the analysis of bioenergetic function in purified mitochondria 
using the Seahorse Biosciences XF24 Flux Analyzer. Pyruvate/Malate and ADP, 
Oligomycin, FCCP, or Rotenone and Succinate were injected sequentially through ports 
A, B, C, and D, respectively, in the Seahorse Flux Pak cartridges to yield final 
concentrations of 5 mM (Pyruvate), 2.5 mM (Malate), 1mM (ADP), 1 μg/ml (Oligomycin), 
1 μM (FCCP) and 100 nM (Rotenone), 10 mM (Succinate) respectively.  
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The following sequence was utilized for analysis following 1 week exposure to TCE and 
TBI:  
Protocol for standard mitochondrial analysis 
Step Command 
1 Calibrate probes 
2 Mix 1 minute 
3 Time delay 1 minute and 30seconds 
4 Mix 25 Seconds 
5 Measure 2 minutes 
6 Mix 1 minute 
7 inject Port A (Pyruvate/Malate/ADP) 
8 Mix 25 Seconds 
9 Measure 2 minutes 
10 Mix 1 minute 
11 inject Port B (Oligomycin) 
12 Mix 25 Seconds 
13 Measure 2 minutes 
14 Mix 1 minute 
15 inject Port C (FCCP) 
16 Mix 25 Seconds 
17 Measure 2 minutes 
18 Mix 1 minute 
19 inject Port D (Rotenone/Succinate) 
20 Mix 25 Seconds 
21 Measure 2 minutes 
   
Statistical analysis: 
 All experimental groups contained 3-6 animals/group. All data were evaluated 
with a two-way analysis of variance (2-way ANOVA) followed by a post-hoc Bonferroni 
test with significance set at p<0.05. 
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Results: 
 
Motor impairment occurs following exposure to TCE and a moderate TBI 
 
Motor impairment is the major functional pathology associated with Parkinson’s 
disease. To investigate the potential of this multifactorial model to produce behavioral 
impairment, two behavioral tests were utilized: the Rotarod and Cylinder Test. Animals 
were tested on the Rotarod 12 days post TBI and it was found that following exposure to 
TCE and a moderate CCI a significant reduction of approximately 50% (Figure 2.1A, 
p<0.01) in the amount of time spent on the Rotarod was observed, indicating impairment 
in motor coordination and balance. At 30 days post TBI animals were analyzed using a 
cylinder test to determine longer-term deficits in forepaw usage. With the cylinder test a 
significant reduction in the usage of the contralateral forepaw was observed in animals 
that were exposed to TCE and a moderate CCI, which decreased to 34% (Figure 2.1B, 
p<0.05) of control animals. With the decrease in forepaw usage only being present 
following a dual exposure to both TCE and a moderate CCI there is again support for a 
dual injury mechanism. Both behavioral tests indicate that the dual injury consisting of 
TCE exposure and a moderate TBI is required for functional deficits to appear and that 
any of the single insults tested are incapable of producing these functional deficits. 
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Figure 2.1: Exposure to TCE and a moderate TBI synergistically interact resulting 
in functional impairment: 
 
 
 
 
 
 
 
 
 
 
 
 
Exposure to both TCE for 2 weeks and a moderate controlled cortical impact TBI result 
in significant motor impairment. A) Twelve days after the TBI animals exhibited 
significant motor impairment as exhibited by a reduced ability to stay on a rotating rod. 
Animals exposed to TCE and a moderate TBI have approximately a 50% reduction in 
the length time able to stay on the Rotarod.  B) Thirty days after the TBI forepaw usage 
was assessed using the cylinder test and contralateral forepaw usage decreased to 
34%. Both behavioral tests show the necessity for both insults to be present before 
functional impairment occurs. 
 
#=p<0.01, *=p<0.05; n=6; 2-Way ANOVA with Bonferroni post-test; Mean±SE 
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Exposure to TCE and a moderate TBI leads to a loss of tyrosine hydroxylase 
positive neurons in the substantia nigra 
 
 The major histological feature of postmortem Parkinson’s disease diagnosis is 
the loss of dopamine neurons in the substantia nigra (SN). Following exposure to either 
TCE or TBI alone there was no significant loss of TH positive neurons in the SN, 
however, following the dual injury with TCE and either a mild  or moderate cortical 
impact there was a 13-17% loss of TH positive neurons in (Figure 2.2A, P<0.05). The 
presence of a significant loss of TH+ cells only following the dual injury indicates that 
exposure to both TCE and TBI can lead to a synergistic loss of dopamine neurons in the 
SN and produce the major histological symptom of PD even with injury levels which are 
incapable of independently producing pathology. To determine if the loss of TH+ cells 
was the result of cell death or a loss of the tyrosine hydroxylase protein, Nissl positive 
cells were also counted. Nissl staining revealed no significant loss of cells indicating that 
the loss of TH+ neurons was the result of a loss of tyrosine hydroxylase and not cell 
death. 
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Figure 2.2 Exposure to TCE and TBI interact and result in TH-positive neuron loss 
in the substantia nigra: 
 
 
 
 
 
 
 
 
 
 
 
Exposure to both TCE for 2 weeks and a mild or moderate controlled cortical impact TBI 
resulted in significant decreases in the number of TH-positive neurons in the substantia 
nigra at 30 days post TBI. A) The dual injury consisting of TCE exposure and a TBI brain 
injury resulted in a 13-17% loss of dopamine neurons in the substantia nigra. B) 
Quantification of Nissl cells in the substantia nigra did not reveal any measurable 
amount of cell loss indicating the loss of TH-positive neurons is due to a loss of the TH 
protein and not the loss of cells. C) Representative images of the substantia nigra 
stained for TH. 
*=p<0.05; n=6; 2-Way ANOVA with Bonferroni post-test; Mean±SE 
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Exposure to TCE and TBI does not affect striatal tyrosine hydroxylase fiber 
density or levels of the dopamine transporter and dopamine receptor: 
 
 Following the loss of dopamine neurons in the substantia nigra in human PD 
there is a resulting loss of both TH+ fibers and the pre-synaptic dopamine transporter 
(DAT) in the striatum along with an increase in the type-2 post-synaptic dopamine 
receptor (D2R). Following either exposure to TCE, TBI, or both, no changes were 
observed in the area of fibers positive for tyrosine hydroxylase in the striatum (Figure 
2.3A). Additionally, there were no observable changes in the levels of DAT or D2R 
following any of the single insults or the dual injury (Figure 2.3C,D). 
 
Exposure to TCE does not affect cortical tissue loss following TBI 
 Following a controlled cortical impact (CCI) injury there is the formation of a 
cortical cavity which results from the loss of neuronal tissue. Given the ability for TCE to 
impair mitochondrial function, and the role mitochondrial dysfunction plays in post-TBI 
cortical tissue loss, the amount of spared cortical tissue was measured in both single 
and dual injured animals. Following a moderate CCI there is approximately a 30% loss 
of tissue (Figure 2.4A, *=p<0.0001). Exposure to the mitochondrial toxin TCE prior to the 
CCI did not lead to an increase in the size of the cortical lesion (Figure 2.4A). Unlike the 
behavioral results, there was no additive effect in the cortex following exposure to both 
TCE and TBI. 
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Figure 2.3 Exposure to TCE, TBI, or the dual injury does not lead to striatal 
changes in TH-fibers, DAT, and D2R. 
 
 
 
 
 
 
 
 
 
 
Neither exposure to TCE for 2 week, a mild or moderate TBI, nor any combination of the 
insults resulted in histological deficits in the striatum. A) The amount of area in the 
striatum immunoreactive for TH was quantified and no reduction in TH-positive fibers 
was measured. B) Representative images of the striatum stained for TH. C,D) Western 
blot analysis for levels of the dopamine transporter and type-2 dopamine receptor 
revealed no changes in either protein. n=6; 2-Way ANOVA; Mean±SE 
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Figure 2.4: Exposure to TCE prior to a moderate TBI does not increase cortical 
tissue loss. 
 
 
 
 
 
 
 
Animals which were exposed to TCE for 2 weeks prior to a moderate TBI did not exhibit 
an increase in the amount of cortical tissue loss. A) With this model and moderate TBI 
resulted in approximately a 30% loss of cortical tissue at 30 days post-injury. Exposure 
to TCE had no effect on the loss of cortical tissue. B) Representative images of Nissl 
stained cortex 30 days post-injury. 
*=p<0.0001; n=6; 2-Way ANOVA with Bonferroni post-test; Mean±SE 
 
 
Two week TCE exposure impairs mitochondrial bioenergetic function in the 
striatum 
 Mitochondrial dysfunction is a common feature of TBI, PD, and TCE exposure. 
The ability for both TBI and TCE exposure to independently inhibit mitochondrial function 
is hypothesized to be a potential mechanism allowing these insults to interact and 
increase pathology. Mitochondria were isolated six hours after the CCI and total 
mitochondria from both the striatum and substantia nigra were analyzed to determine 
mitochondrial bioenergetic function. No reductions in mitochondrial function were  
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observed in the substantia nigra six hours after the TBI or following the two week 
exposure to TCE (Figure 2.5A). At six hours post injury exposure to TCE produced 
significant mitochondrial impairment in the striatum which was observed by reductions in 
both the basal and maximal rates of Complex I dependent oxygen consumption by 
approximately 75% (Figure 2.5B, *=p<0.05). Exposure to the TBI alone resulted in a 
non-significant trend towards reduced Complex I function in by approximately 30% in the 
striatum. The combination of TCE exposure and a TBI did not result in a measureable 
change mitochondrial function in the striatum when compared to TCE exposure alone. 
 
Figure 2.5: Two week exposure to TCE results in decreased bioenergetics in the 
striatum. 
 
 
 
 
 
Animals were exposed to TCE for 2 weeks and then subjected to a moderate TBI and 
mitochondrial tissue was isolated from the striatum and substantia nigra six hours post-
injury. A) Analysis of mitochondrial bioenergetic function in the substantia nigra revealed 
no significant difference between any of the treatment groups. B) Exposure to TCE for 2-
weeks produced significant reductions of approximately 75% in Complex I dependent 
basal and maximal rates of mitochondrial oxygen consumption. TBI alone resulted in a 
trend towards reduced mitochondrial function in the striatum, however, this decrease did 
not reach significance. 
 
*=p<0.05, n=5-6; 2-Way ANOVA with Bonferroni post-test; Mean±SE 
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One week exposure to TCE followed by TBI results in synergistic mitochondrial 
dysfunction in the striatum 
 Given the 75% reduction in Complex I driven mitochondrial function in the 
striatum following 2 week exposure to TCE (Figure 2.5), and the difficultly this produces 
in elucidating whether an interaction between TCE exposure and TBI exists, additional 
animals were subsequently administered TCE for only 1 week. Following exposure to 
TCE alone for 1 week there was not a reduction in Complex I driven mitochondrial 
respiration. Similarly to the previous 2 week exposure studies, a moderate TBI resulted 
in a non-significant decrease in mitochondrial bioenergetic function of approximately 
30%. When the 1 week exposure to TCE was combined with a moderate TBI, 
mitochondrial bioenergetic function was reduced by approximately 50% (Figure 2.6, 
*=p<0.05). These studies indicate that TCE and TBI are capable of interacting at the 
mitochondrial level which leads to significant mitochondrial dysfunction requiring the 
presence of both insults.  
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Figure 2.6: One week exposure to TCE followed by a moderate TBI results in 
mitochondrial dysfunction in the striatum. 
 
 
 
 
 
 
Exposure to either TCE for 1 week of a moderate TBI did not result in significant 
mitochondrial dysfunction in the striatum. When the two separate insults were combined 
together there was a significant reduction in the Complex I driven rate of mitochondrial 
oxygen consumption. The dual injury paradigm resulted in significant mitochondrial 
impairment which was measured as  a 50% reduction in mitochondrial respiration. 
*=p<0.05, n=3-4; 2-Way ANOVA with Bonferroni post-test; Mean±SE 
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Discussion: 
It has been proposed that in humans, the development of Parkinson’s disease 
(PD) may involve a multifactorial mechanism (Semchuk et al., 1993). Genetic factors (for 
review see (Nuytemans et al., 2010)), age (Naoi and Maruyama, 1999), and the toxin 
MPTP (Langston et al., 1983, Langston and Ballard, 1983) have been shown to 
independently lead to the development of PD in humans independently of other factors, 
however, with the vast majority of other insults, such as TBI, or environmental exposures 
it has been difficult to show causation for disease development (for review see (Veldman 
et al., 1998)). Previous work from our group has shown that both in humans and rodents 
chronic exposure to trichloroethylene (TCE) is capable of producing pathologic features 
of PD such as motor impairment, loss on dopamine neurons in the substantia nigra and 
striatal deficits in tyrosine hydroxylase (Gash et al., 2008, Liu et al., 2010). Even though 
chronic high dose exposure is capable of leading to the development of Parkinsonism or 
complete PD in both humans and animals (Gash et al., 2008, Liu et al., 2010), it is 
unknown how many individuals would be exposed to high levels of TCE chronically. In 
the present studies we investigated the potential for a lower exposure to TCE combined 
with a traumatic brain injury (TBI) to produce a multifactorial model of PD. These studies 
provide an initial indication that TCE and TBI can interact in a multifactorial mechanism. 
It has been established using various combinations of insults and toxin 
exposures that a multifactorial injury can produce a greater insult both in vitro (Arundine 
et al., 2003, Arundine et al., 2004, Fei and Ethell, 2008) and in vivo (Thiruchelvam et al., 
2000a, Thiruchelvam et al., 2000b, Ling et al., 2006). In neuronal culture, cells which are 
exposed to a mechanical stretch injury prior to NMDA exposure are made more 
susceptible to the toxic insult (Arundine et al., 2003, Arundine et al., 2004). In rodents it 
has been shown that prenatal toxin exposure can make animals more susceptible to 
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future insults, resulting in a progressive model of PD (Ling et al., 2006), and that 
multifactorial toxin exposure can produce a greater insult than exposure to a single insult 
(Thiruchelvam et al., 2000a, Ling et al., 2006). Epidemiological studies have attempted 
to find a potential link between TBI and PD (Bower et al., 2003). However, a causative 
link between TBI and PD has been difficult to show and as a result it has been proposed 
that the link between TBI and PD may involve a multifactorial mechanism (Semchuk et 
al., 1993). 
The major pathological symptoms of PD are progressive impairment in motor 
control and loss of dopamine neurons in the substantia nigra. To investigate the potential 
for a dual injury model to recapitulate the motor impairments and cell loss observed in 
PD, both Rotarod and cylinder testing were utilized to assess motor function and 
tyrosine hydroxylase (TH) staining was utilized to analyze both dopamine neurons in the 
substantia nigra and dopamine fibers in the striatum. For our initial studies two different 
severities for the TBI were utilized since it has been shown in human studies that the 
severity of the injury significantly affects the link between TBI and PD (Bower et al., 
2003). Following a 2 week exposure to TCE and a moderate controlled cortical impact 
(CCI) TBI, impairments were observed both with the Rotarod (Figure 2.1A) and cylinder 
test (Figure 2.1B) indicating not only that the dual injury paradigm in these experiments 
is required for motor impairment but also that a moderate and not a mild TBI is required 
for the presentation of motor impairment. To determine whether a loss of dopamine 
neurons in the substantia nigra was linked to the dual injury, TH-positive neurons were 
quantified and it was observed that, in contrast to the behavioral data which indicated 
that TCE exposure and a mild TBI did not result in dysfunction, exposure to TCE and 
either a mild or a moderate TBI is sufficient to produce a loss of TH-positive neurons 
(Figure 2.2A). Additionally, the loss of TH-positive cells was also shown to be the result 
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of a loss of the TH protein and not cell loss, since quantification of Nissl cells did not 
result in any group differences (Figure 2.2B). Though the behavioral analysis and TH-
positive cell counts did reach statistical significance in these studies, the deficits were 
not as substantial as we hypothesized they would be. The results indicate that the 
individual insults are insufficient to produce any impairment independently which is 
desirable in this model since the major goal was to show a dual injury effect, however, 
different injury parameters may have yielded us a more substantial dual injury model. 
Specifically with regards to the TBI, had the injury been located directly over the striatum 
or been more severe we may have been able to observe more profound alterations in 
our endpoints. 
Since a moderate TBI was required for motor impairment to occur, further 
experiments were conducted utilizing this level of injury. Given the loss of TH-positive 
neurons, the area of TH-positives fibers in the striatum was determined. As was 
expected for only a 13-17% loss of cells in the substantia nigra, no measurable decrease 
in TH-fiber density was observed in the striatum (Figure 2.3A). Since the levels of the 
dopamine transporter have been shown to be reduced in a similar model of TBI which 
utilizes a severe injury (Wagner et al., 2005), striatal tissue was analyzed both for levels 
of the dopamine transporter (DAT) and the type-2 dopamine receptor (D2R). Following 
either single insult or the dual injury, no reductions in the levels of DAT or D2R were 
observed one month following the injury (Figure 2.3C,D). The lack of a reduction in the 
DAT is likely the result of a more central and less severe TBI than previous reports 
(Wagner et al., 2005). Further tissue analysis was conducted looking at cortical tissue 
loss following the dual injury paradigm. A 30% loss of cortical tissue was observed 
following the moderate TBI and exposure to TCE did not increase this loss (Figure 2.4A). 
Since there was not an increase in cortical tissue loss, the data suggests that the main 
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TCE effects are not in the cortex. The lack of observable changes in the levels of DAT 
and D2R further indicate that at one month following the dual injury, this paradigm 
produces a very mild dual injury model.  
Mitochondrial dysfunction is a major pathological mechanism involved in TBI 
(Sullivan et al., 1998a, Sullivan et al., 1999c, Singh et al., 2006) as well as a common 
factor of many toxins linked to PD (Nakamura et al., 2000, Sherer et al., 2003, Gash et 
al., 2008, Liu et al., 2010). It has been previously shown that either exposure to TCE 
(Gash et al., 2008, Liu et al., 2010) or the metabolite TaClo (Bringmann et al., 1995a, 
Janetzky et al., 1995) are capable of producing significant impairment in mitochondrial 
bioenergetic function. In order to understand if exposure to TCE is capable of leading to 
greater mitochondrial dysfunction following TBI, animals were exposed to TCE for two 
weeks and then subjected to a moderate CCI injury. Tissue was isolated from both the 
striatum and substantia nigra six hours after the brain injury since mitochondrial 
dysfunction has been shown to peak early after TBI (Singh et al., 2006). Samples from 
the substantia nigra revealed no significant impairments in mitochondrial function at six 
hours after the injury (Figure 2.5A). In contrast to the lack of an effect in the substantia 
nigra at six hours post-TBI, the striatum exhibited significant mitochondrial dysfunction. 
In these studies a significant reduction in mitochondrial function was produced as a 
result of exposure to TCE (Figure 2.5B), which made it difficult to observe a dual injury 
effect since it appears that mitochondrial bioenergetic function has potentially reached a 
maximal amount of impairment which cannot be increased. This bottoming out effect 
likely occurs since any further decrease in bioenergetic function would most likely lead to 
cell death and the mitochondria would no longer survive for analysis. Exposure to TCE 
resulted in approximately a 75% reduction in both basal and maximal rates of Complex I 
dependent mitochondrial bioenergetic function. A trend towards a reduction in 
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mitochondrial function was observed in the striatum following exposure to TBI alone, 
however, this effect did not reach significance. As predicted for the other endpoints, had 
the TBI occurred directly over the striatum it is hypothesized that this decrease would 
become more pronounced. Given the large reduction in mitochondrial function in the 
striatum following the 2 week exposure to TCE and the difficulty this presents for 
measuring increases in this deficit due to a subsequent TBI, further experimentation was 
conducted using a 1 week exposure to TCE. Following exposure to TCE for 1 week 
there was no decrease in Complex I driven mitochondrial function in the striatum. As 
observed in the previous mitochondrial experiments, exposure to the TBI alone resulted 
in a non-significant trend towards mitochondrial impairment of approximately 30%. When 
the 1 week exposure to TCE was combined with the TBI, a significant reduction of 
approximately 50% was observed in the striatum six hours after the injury (Figure 2.6). 
The experiments utilizing the 1 week exposure of TCE show that the two insults are 
capable of interacting at the mitochondrial level to produce a greater amount of 
dysfunction than either insult alone is capable of. 
The requirement for a multifactorial injury to produce the pathology shown in this 
study is in line with what has been seen in humans, where many insults have been 
determined to be risk factors for the development of human PD, but it has been difficult 
to show whether these same risk factors are able to independently produce pathology. 
This dual injury model utilizes toxin and injury levels which are individually insufficient to 
produce motor impairment or a loss of TH-positive neurons, hallmarks of human PD. 
However the dual injury produces significant reductions in both outcomes, indicating that 
sub-acute exposure to multiple insults can interact to produce a significant injury and 
lead to disease development. Previous studies have shown that insults targeting the 
striatum can result in the progressive loss of TH-positive neurons in the substantia nigra 
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(Sauer and Oertel, 1994) and that striatal mitochondrial inhibition results in DA 
dysfunction (Zeevalk et al., 1997). Since both TCE exposure and TBI are capable of 
producing reductions in striatal mitochondrial function, it is predicted that this 
mitochondrial impairment leads to the reductions in TH-positive nigral neurons observed 
in these studies in the same way as other models. What is striking about this study is 
that motor impairment is present with levels of dopamine neuron loss which are lower 
than typically seen from nigral neuron loss alone (Lee et al., 1996). The likely cause for 
the motor impairment in this model is that in addition to the observed nigral deficits there 
is striatal mitochondrial dysfunction which impairs normal synaptic function and a loss of 
cortical tissue. The presence of neuronal death and dysfunction in multiple 
interconnected regions of the brain likely leaves the system unable to overcome the 
combinatorial insult. Given the lack of a significant decrease in tyrosine hydroxylase 
positive fiber density in the striatum it would be unexpected that the typical therapeutic 
utilized in humans, levodopa, would be capable of alleviating any of the motor 
impairment. Since a percentage of human PD patients are non-responsive to levodopa, 
this dual injury paradigm my recapitulate certain aspects of non-levodopa responsinve 
PD.  
Our initial study sought to utilize insults which would be insufficient to produce 
pathology in our endpoints since we wanted to show a dual injury effect. However, 
utilizing insults that do not independently produce pathology makes it difficult to know 
what levels of the insults are ideal for this dual injury model. The results presented in 
these studies do suggest that the dual injury hypothesis is valid; however, the lack of 
overwhelming histological changes makes determining the role of these changes in PD 
development difficult to prove. The lack of an effect on striatal protein expression at 30 
days post-TBI suggests that the injury parameters utilized in the present study are not 
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sufficient to elicit permanent changes in the striatum. Given the changes in striatal 
proteins in human PD patients (Donnemiller et al., 2000) and that other animal models 
recapitulate some of these changes (Wagner et al., 2005), future attempts to combine a 
toxic insult with TBI should focus on injury parameters which directly target the striatum 
and are thus more likely to elicit these changes. The mitochondrial results following the 1 
week exposure to TCE do show that these two insults can interact at the mitochondrial 
level to produce significant dysfunction. 
These studies are the first to shown an in vivo dual injury model which utilizes 
TBI, a major risk factor of PD, as a component of the injury paradigm. These studies 
further implicate the mitochondria as a central component of TCE exposure, TBI, and 
PD, especially in the striatum. Given the lack of increased cortical tissue loss when TCE 
is administered prior to the TBI and previous evidence that more chronic exposure  to 
TCE can lead to deficits in the substantia nigra (Gash et al., 2008, Liu et al., 2010), it is 
likely that the basal ganglia, especially the striatum, is more susceptible to TCE 
exposure. Previous studies have shown that other mitochondrial toxins do appear to 
predominately affect the basal ganglia (Koutouzis et al., 1994, Ferrante et al., 1997) and 
that this effect is likely due to a these regions having lower levels of spare electron 
transport chain capacity (Fern, 2003).  These studies provide further support that TBI 
can play a role in the development of PD and that a multifactorial injury paradigm can 
produce greater pathology. Given the observed deficits in this study, future work 
incorporating TBI in a dual injury PD model should attempt to more directly target the 
basal ganglia in order to have a greater ability to elicit deficits. The present findings do 
support the concept of a multifactorial mechanism for the development of PD and further 
experimental refinement of this model will help in elucidating the complex interactions of 
these insults across multiple brain regions. 
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A short coming in this work, which could be addressed with further 
experimentation, is the limited time points utilized for the various endpoints. The initial 
goal of the project was to determine if TCE and TBI could interact and produce a dual 
injury model of PD. Given that PD is a chronic condition which does not improve on its 
own, acute time points were not utilized for the behavioral analysis. Previous work in 
rodents has shown that following many experimental models of traumatic injury there is 
a spontaneous recovery in behavioral function which occurs. Since the individual 
behavioral tests were only conducted on single days, we are unable to determine in the 
dysfunction is constant, improves with time, or gets worse with time. Future 
experimentation with the model would be made stronger if behavioral analysis for the 
individual tasks were performed over multiple days, both acute and chronic, for each 
test. In addition to performing more time points for the behavioral analysis, the 
quantification of dopamine neurons in the substantia nigra would be made stronger by 
the addition of later time points. In the present experiments cell counts were performed 
30 days post injury, only a loss of phenotypic dopamine neurons was observed. Given 
the progressive nature of PD in humans, determining the number of dopamine neurons 
in the substantia nigra at more time points would provide at least two benefits. First, it 
could be further determined in the loss of phenotypic dopamine neurons continued or if 
the cells went on to die or were able to recover and start producing dopamine again. 
Secondly, by performing cell counting at later time points it could be concluded if cell 
loss increases with time in a similar manner as observed in humans. By further 
expanding the time points for the behavioral and histological analysis the ability to 
determine if this model results in progressive degeneration, similar to what is observed 
in humans, and to further understand the interaction of the two insults would be made 
stronger.  
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In addition to expanding the number of time points utilized in these studies, 
incorporation of additional endpoints would increase the understanding of this model. In 
human PD there is the development of α-synuclein inclusions and exposure to TCE in 
rats has also been shown to result in the formation these inclusions. Given the link 
between both TCE induced α-synuclein inclusion formation and the occurrence of these 
inclusions in human PD, this endpoint would help both by providing and endpoint which 
one of the factors in this model, TCE, is already known to affect and could be potentially 
made worse by a second endpoint as well as providing further endpoints shown to be 
affected in human PD. Additionally, markers of neuronal death such as silver-stain or 
Flurojade staining could be utilized which would help to assess damage not only in the 
cortex of basal ganglia as has already been performed but also in other regions of the 
brain which as of yet have not been utilized for analysis. Furthermore, analysis of the 
post-synaptic neurons could provide significant understanding about the current model. 
The present experiments looked mainly at the pre-synaptic dopamine neurons which 
project from the substantia nigra to the striatum. Recent unpublished data has shown 
that following traumatic brain injury in rats there is a significant alteration of the 
phosphorylation status of the post-synaptic protein DARPP-32 (bales poster). Given the 
role this protein plays in the normal function of dopaminergic signaling in the basal 
ganglia (for review see (Fisone et al., 2007) it would be expected that changes in the 
proteins regulation would affect basal ganglia functioning. Given the previous evidence 
of changes to this protein following TBI, and that many other post synaptic proteins may 
have been altered in the present studies which result in deficits in motoring functioning, 
detailed analysis of the post-synaptic neurons would help in determining if TBI, TCE, or 
the interaction of the two affect the pre-synaptic and post-synaptic neurons differently. 
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As mentioned previously, significant modification to the method of performing the 
TBI would be expected to have a profound effect on the endpoints in the current model. 
Previous experiments utilizing cortical impact to look at changes to the dopaminergic 
system have positioned the injury directly over the striatum and utilized a more severe 
impact and this injury paradigm results in more significant changes than were observed 
in the experiments present here (Wagner et al., 2005, Wagner et al., 2009). Had we 
utilized different injury parameters we expect that the observed effects of the TBI on the 
striatum would be more severe. What should also be cautioned against though is 
producing too severe of an injury which would prevent or hinder the ability to observe a 
dual injury affect. As was observed with the 2 week TCE mitochondrial analysis, if the 
mitochondrial dysfunction is too large it can be impossible to determine if the dual injury 
resulted in more impairment. If the location of the TBI is altered in future experiments 
some endpoints such as changes to proteins like the DAT or D2R could become 
significant, however, other endpoints such as mitochondrial dysfunction may increase to 
the point where a dual injury effect is not able to be observed. In addition to changing the 
location of the TBI, changing the type of TBI could have a profound effect on the effect of 
the dual injury and on the understanding of the developed of human PD and the role of 
TBI in disease development. Recent unpublished work from the University of Kentucky 
has indicated that moderate severity diffuse brain injury results in significant dysfunction 
to the substantia nigra (Lifshitz poster). Following this injury paradigm there is a 
significant increase in microglial activation and reactive astrogliosis along with a loss of 
neurons in the substantia nigra. The cell loss associated with this TBI paradigm is 
greater at month following the brain injury alone than was observed with the TCE TBI 
paradigm present here. Future work looking at the interaction of TCE and TBI should 
strongly consider model of TBI utilized in the experiments since damage to the 
substantia nigra and potentially the rest of the basal ganglia could be must greater if a 
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diffuse brain injury instead of a cortical impact based brain injury is combined with the 
TCE exposure.  
The current studies are limited by endpoints and time points utilized for the 
determination of the insults both independently and together. Future work on this model 
should seek to expand the endpoints utilized for histological analysis as well as expand 
the number of time points utilized for motor function analysis. Changes to both of these 
aspects of the current project would greatly improve the ability to determine the effect 
the insults have and whether the model truly does represent of potential mechanism for 
the development of PD in humans. Additionally, and potentially more siginificantly than 
adding and expanding endpoints, careful planning should be performed to determine 
what model(s) of TBI should be utilized for future studies. It could be of particular interest 
to independtly test both changes to the parameters of the current model as well as 
changing to a more diffuse injury paradigm since this would give the best ability to 
determine not only if TBI plays a role in the development of human PD but also what 
type(s) of TBI produce the most significant damage to the basal ganglia. These studies 
provide an initial indication that TCE and TBI may be able to interact and produce more 
pathology than either insult alone and future experiments should be able to help in 
extending the findings of the current work. 
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Chapter 3 
Regional mitochondrial function and toxin susceptibility 
 
Introduction: 
It is understood that regional differences play an important role in mitochondrial 
function (for review see (Dubinsky, 2009)), however, there is limited evidence profiling 
basal mitochondrial function or the susceptibility to mitochondrial inhibitors across 
multiple brain regions. As shown in the previous chapter, the toxin trichloroethylene has 
been shown to affect mitochondria in the striatum and substantia nigra differently, 
however, there is no good understanding at this time why the two regions are 
differentially affected. Many different factors have been shown to play a role the 
observed regional differences in mitochondrial function such as enzyme activities 
(Ryder, 1980, Gupta et al., 2000), requirements for oxidative phosphorylation (Hevner et 
al., 1995), neuronal activity (Nie and Wong-Riley, 1996, Wong-Riley et al., 1997), and 
spare respiratory capacity (Fern, 2003). Mitochondrial function has been shown to be 
tightly linked with the cellular environment and events such as neurotransmitter induced 
increases in intracellular calcium have been shown to directly affect the activity of 
mitochondrial enzymes (Denton et al., 1988). Aside from rapid induction of changes in 
mitochondrial function, regions which have high utilization of glucose have been shown 
to contain more mitochondrial protein as determined by the level of Cytochrome Oxidase 
(Humphrey and Hendrickson, 1983), indicating that long term changes in the regulation 
of mitochondrial bionenergetics also exist. Additionally, the opposite effect has been 
shown by reducing the activity of a particular brain region either by administration of the 
sodium-channel blocker tetrodotoxin (Nie and Wong-Riley, 1996) or by blocking 
peripheral sensory input (Tieman, 1985). These reductions in neuronal activity have 
been shown to result in decreased amounts of mitochondria and mitochondrial proteins 
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(Tieman, 1985, Nie and Wong-Riley, 1996). It is generally believed that one of the most 
important factors controlling regional mitochondrial differences is higher levels of 
neuronal activity which demand more ATP (Sokoloff et al., 1977). Even though regional 
differences in oxygen consumption and mitochondrial numbers have been shown to be 
linked to neuronal activity, this does not directly indicate that the individual mitochondria 
are actually different. There are mitochondrial enzymes which do show regional 
differences (Ryder, 1980, Gupta et al., 2000), however, this is not the case for every 
enzyme. Many components of the TCA cycle have been shown to have similar activity 
levels across brain regions suggesting that the mitochondria in different brain regions 
may function similarly to each other (Marzatico et al., 1987, Curti et al., 1989, Dagani et 
al., 1989, Villa and Gorini, 1991). A major difficulty in understanding whether regional 
differences in mitochondrial function exist is that most studies typically utilize very few 
brain regions, whole brain homogenates, or focus on synaptic versus non-synaptic 
mitochondria. Factors such as the control of oxygen consumption by electron transport 
chain components are similar in the cortex and hippocampus but differ significantly 
between synaptic and non-synaptic mitochondria from the same brain region (Pathak 
and Davey, 2008). The activity of Complex II of the mitochondrial electron transport 
chain has also been shown to be similar between brain regions even though it differs 
from non-neuronal tissue such as the heart and the liver (Mirandola et al., 2010). 
Analysis of currently available experimental data suggests that the individual 
mitochondria may function similarly across brain regions (Dubinsky, 2009) even though 
some proteins have shown activity differences. Even though evidence suggests oxygen 
consumption by isolated mitochondrial may be similar across brain regions, the 
assumption has yet to be directly tested by looking at mitochondrial consumption of 
oxygen across brain regions within a single study. 
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Beyond just basal mitochondrial function, another aspect of regional 
mitochondrial differences is the susceptibility of different brain regions to inhibition of the 
mitochondrial electron transport chain (ETC). It has been established that toxins such as 
3-nitropropionic acid or trichloroethylene produce regionally specific mitochondrial 
dysfunction when given systemically (Beal et al., 1993, Gash et al., 2008) even though it 
would be expected that more than just the affected brain regions are actually exposed to 
the toxins. Mirandola et al. showed that there are regional differences in the activation of 
the mitochondrial permeability transition by 3-NP even though inhibition of Complex II 
enzyme activity is affected proportionally across brain regions (Mirandola et al., 2010). A 
significant factor which likely plays a direct role in the regionally different susceptibilities 
to mitochondrial inhibitors is the amount of spare respiratory capacity for a given 
complex within a specific brain region (Fern, 2003). Interestingly, the regions with the 
lowest spare respiratory capacities for a given mitochondrial complex appear to be the 
ones most susceptible to inhibitors blocking that particular complex (Fern, 2003). The 
current evidence on the effect of mitochondrial inhibitors across brain regions is difficult 
to fully interpret since many of the studies only take limited factors into account. Davey 
et al. showed that mitochondrial inhibitors which block different ETC complexes can 
produce significantly different effects on oxygen consumption, however, the study 
utilized whole brain mitochondria and so determining if regional differences exist is 
impossible to determine (Davey et al., 1998). Mirandola et al. investigated the effect of 3-
NP on Complex II enzyme activity across brain regions, however, when investigating the 
effect of 3-NP of oxygen consumption only a minimally dissected brain sample was 
utilized (Mirandola et al., 2010). Studies investigating systemic toxin exposure of 
mitochondrial toxins have shown regionally specific histological damage (Beal et al., 
1993, Liu et al., 2010) which suggests that mitochondrial function may be differentially 
affected across brain regions. Since the amount of inhibition of enzyme activity is not 
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always directly proportional to the amount of inhibition of oxygen consumption (Davey et 
al., 1998), it is important to investigate both the inhibition of enzyme activity and oxygen 
consumption in order to determine whether effects differ across brain regions. Given the 
evidence which shows regionally specific damage following systemic toxin exposure, it 
was hypothesized that regional differences in basal mitochondrial function or the 
susceptibility of the mitochondria to Complex I or Complex II inhibitors may exist which 
underlie the regionally specific histological damage. 
 
Methods: 
All studies were approved by the University of Kentucky Animal Care and Usage 
Committee. Throughout all of the experiments, 16 week old male Fischer 344 rats 
(Harlan) were utilized.  
 
Mitochondrial isolation:   
Total mitochondria were isolated using differential centrifugation, nitrogen 
disruption, and a Ficoll gradient as previously reported. Animals were asphyxiated with 
CO2 and rapidly decapitated. Following decapitation, the brain was rapidly removed and 
placed in a beaker of ice-cold isolation buffer (215mM Mannitol, 75mM Sucrose, 0.1% 
BSA, 1mM EGTA, and 20mM Hepes at pH 7.2) to briefly cool. Anatomical regions of 
interest were rapidly dissected apart and the tissue placed in ice-cold isolation buffer 
until homogenization. Samples were homogenized and then centrifuged at 1300xG for 3 
minutes at 4oC. Following the first spin the supernatant was placed in a fresh tube and 
the pellet was resuspended in isolation buffer and spun at 1300xG for 3min at 4oC. The 
supernatants from the first and second spins were collected in separate tubes and spun 
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at 13,000xG for 10 minutes at 4oC. The pellets from both tubes were combined, 
resuspended in 400ul isolation buffer and placed in a nitrogen bomb at 1,200psi for 
10min. The pressure in the nitrogen bomb was rapidly released and the sample was 
placed as the top layer on a Ficoll separation column which consisted of a 10% Ficoll 
layer and a 7.5% Ficoll layer. The Ficoll column with sample was centrifuged at 
100,00xG for 30min at 4oC using a Beckman SW 55Ti rotor and ultra-centrifuge. The 
final mitochondrial pellet was resuspended in isolation buffer without EGTA to yield a 
final concentration of approximately 10mg/ml, and stored immediately on ice. Protein 
concentrations for each sample were determined with all the samples on the same plate 
using the BCA protein assay kit and measuring absorbance at 560nm with a Biotek 
Synergy HT plate reader (Winooski, Vermont).  
 
Preparation of mitochondrial substrates and inhibitors: 
Stocks of mitochondrial substrates were prepared as follows and stored at -20 oC 
until further use. The concentrations for mitochondrial substrates were based upon 
experience with the Clark-type oxygen electrode (Pandya et al., 2007, Pandya et al., 
2009) and optimized to obtain mitochondrial bioenergetic profiles which fit with 
previously observed findings obtained with the oxygen electrode. 500mM 
Pyruvate/250mM Malate was prepared by combining 550 mg Pyruvate (Sigma P-2256), 
335 mg Malate (Sigma M-7397), and 200 µl of 1M HEPES in 10 ml diH20 and the pH 
was adjusted to pH 7.2. A 30mM ADP stock was prepared by combining 128.2mg ADP 
(Sigma A-5285) and  200 µl of 1M HEPES in 10 ml diH20 and pH was adjusted to pH 
7.2. A 1mg/ml Oligomycin-A stock was prepared by combining 1 mg Oligomycin-A 
(Biomol CM-111) with 1ml methanol. A 1mM FCCP stock was prepared by combining 
2.542 mg FCCP (Biomol CM-120) with 10 ml 100% ethanol. A 1M Succinate stock was 
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prepared by combining 2.36g Succinic Acid (Sigma S-7501) with 400 µl of 1 M HEPES 
in 20ml in diH20 and the pH was adjusted to pH 7.2. Rotenone was prepared by first 
combining 3.944mg rotenone (Biomol CM-117) with 10ml 100% ethanol for a final 
concentration of 1mM. Rotenone was further serial diluted with 100% ethanol to obtain 
final concentrations of 100uM, 10uM, 1uM, 100nM, and 10nM rotenone. Malonate stock 
was prepared by first combining 1.04g  Malonic Acid (Sigma M1296) with 10mL diH20 
and the pH was adjusted to 7.2 for a final concentration of 5M.  KOH and HCl were 
utilized for all pH adjustments. 
 
Preparation and calibration of Seahorse sensor cartridge sample plate: 
 
A Seahorse Bioscience XF24 extracellular flux analyzer was used to measure 
mitochondrial function in intact isolated mitochondria. The XF24 creates a transient, 7 ul 
chamber in specialized microplates that allows for the determination of oxygen and 
proton concentrations in real time. The day before the planned experiment, 1ml of XF 
Calibrant solution (Seahorse Bioscience) was added to each well of a 24 well dual-
analyte sensor cartridge (Seahorse Bioscience). The sensor cartridge was placed back 
on the 24 well calibration plate and put in a 37 oC incubator without CO2 (Seahorse 
Bioscience) overnight. The day of the experiment, the injection ports on the sensor 
cartridge were loaded with the appropriate mitochondrial substrates or inhibitors at 10X 
concentrations.  Once the sensor cartridge was loaded with all of the experimental 
reagents it was placed into the Seahorse XF24 Flux Analyzer for automated calibration. 
During the senor calibration, isolated mitochondria were then seeded in 50 ul volume of 
respiration buffer containing 2.5 μg or 5 μg of protein (BCA method) per well in 
polyethyleneimine-coated XF24 V7 cell culture microplates. Following the centrifugation 
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of the plates at 2000rpm for 4 minutes at 4oC, 575ul of respiration buffer (215 mM 
mannitol, 75 mM sucrose, 0.1% BSA, 20 mM HEPES, 2 mM MgCl, 2.5 mM KH2PO4 at 
pH 7.2)  at 37 oC was gently added to each well for a final volume of 625ul per well at the 
beginning to the experiment. Plates were immediately placed into the calibrated 
Seahorse XF24 flux analyzer for mitochondrial bioenergetic analysis. 
 
Seahorse protocol for isolated mitochondria: 
The following protocol was utilized for the analysis of bioenergetic function in 
purified mitochondria using the Seahorse Biosciences XF24 Flux Analyzer. 
Pyruvate/Malate and ADP, Oligomycin, FCCP, or Rotenone and Succinate were injected 
sequentially through ports A, B, C, and D, respectively, in the Seahorse Flux Pak 
cartridges to yield final concentrations of 5 mM (Pyruvate), 2.5 mM (Malate), 1mM 
(ADP), 1 μg/ml (Oligomycin), 1 μM (FCCP) and 100 nM (Rotenone), 10 mM (Succinate) 
respectively.  
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The following sequence was utilized for basal functional analysis:  
 
Protocol for standard mitochondrial analysis 
Step Command 
1 Calibrate probes 
2 Mix 1 minute 
3 Time delay 1 minute and 30seconds 
4 Mix 25 Seconds 
5 Measure 2 minutes 
6 Mix 1 minute 
7 inject Port A (Pyruvate/Malate/ADP) 
8 Mix 25 Seconds 
9 Measure 2 minutes 
10 Mix 1 minute 
11 inject Port B (Oligomycin) 
12 Mix 25 Seconds 
13 Measure 2 minutes 
14 Mix 1 minute 
15 inject Port C (FCCP) 
16 Mix 25 Seconds 
17 Measure 2 minutes 
18 Mix 1 minute 
19 inject Port D (Rotenone/Succinate) 
20 Mix 25 Seconds 
21 Measure 2 minutes 
     
 The same protocol was utilized for the log dose response experiments except 
that rotenone or malonate were injected through Ports B, C, and D. For the time 
dependent effect of rotenone administration a modified Seahorse mitochondrial protocol 
was utilized for the repeated measure of oxygen consumption from the same well 
following the injection of various low concentrations of rotenone (10fM, 10pM, 10nM).  
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Analysis of data generated by Seahorse biosciences XF24: 
For optimal analysis of mitochondrial bioenergetic function, the data generated 
by the XF24 was further analyzed beyond the average oxygen consumption ratio 
generated for a given measure. The methods for analyzing the Seahorse data are based 
upon similar protocols for analyzing the rate of oxygen consumption using a Clark-type 
oxygen electrode. During a given measure, the rate of oxygen consumption varies with 
time as substrates bind with their targets or are consumed by the mitochondria. Using 
the Excel software package (Microsoft), point-by-point rates are generated using the 
AKOS algorithm written by Seahorse Bioscience. For Complex I and Complex II 
function, the highest point-by-point rate is taken since as substrates are consumed the 
rate begins to decrease. For the Oligomycin-A rate, an average of the last three point-
by-point rates is taken since the effect of Oligomycin-A can take at least one minute to 
reach maximal effect and an average of the last 30 seconds of the measure provides the 
most consistent result. 
Mitochondrial Complex I assay: 
Mitochondrial Complex I enzyme activity was determined by measuring the 
decrease in NADH absorption at 360nm in the presence and absence of rotenone, as 
previously described (Gash 2008, Brown 2004). Frozen purified mitochondrial were 
thawed and then diluted in 10mM KPO4 pH 7.4 to a concentration of 1ug/ul. Samples 
then underwent three cycles of five minute freezing on dry ice followed by five minutes of 
thawing at 37oC followed by five seconds of sonication. The assay was performed in a 
BioTek Synergy HT plate reader (BioTek, Winooski, VT) with excitation at 360nm and 
emission at 460nm. 6ug of mitochondrial protein was added to 25mM KPO4 pH 7.2, 
5mM MgCl2, 1mM KCN, 1mg/ml bovine serum albumin, and 150uM NADH in a total 
volume of 69ul. Either 1ul of 1mM rotenone or 1ul of 25mM KPO4 pH 7.2 was added so 
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that with and without rotenone samples could be compared. The reaction was started by 
the addition of 30ul of coenzyme Q1 (final concentration 50uM). Enzyme activity was 
calculated by subtracting the change in NADH emission in the absence of rotenone from 
the change in NADH emission in the presence of rotenone. 
 
Mitochondrial Complex II assay: 
Mitochondrial Complex II enzyme activity was determined by measuring the 
change in absorbance of DCIP at 600nm using a BioTek Synergy HT plate reader 
(BioTek, Winooski, VT). Frozen purified mitochondrial were thawed and then diluted in 
10mM KPO4 pH 7.4 to a concentration of 1ug/ul. Samples then underwent three cycles 
of five minute freezing on dry ice followed by five minutes of thawing at 37oC followed by 
five seconds of sonication. 3ug of mitochondrial was added to 200mM KPO4 pH 7.0, 
20mM K-Succinate, 10uM EDTA, 0.01% Triton X-100, 0.5ug/50ul coenzyme Q10, ~20% 
DCIP for a total volume of 50ul. The starting optical density was between 0.6-0.8 at 
600nm and the exact concentration of DCIP was made so that this starting density was 
obtained. The change in absorbance was measured at the beginning of the experiment 
and two minutes later. Enzyme activity was determined by subtracting the final optical 
density from the initial optical density. 
Statistical analysis: 
 For all experiments significance, was set at p<0.05. Analysis of the mitochondrial 
protein dependent rate of Complex I oxygen consumption was performed with a two-
tailed t-test. Comparisons of basal mitochondrial function were conducted using a one-
way analysis of variance followed by post-hoc analysis to determine group differences. 
The log dose response experiments and the time dependent rotenone inhibitory effect 
were analyzed using a two-way analysis of variance followed by post-hoc analysis to 
determine group differences. 
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Results: 
Basal mitochondrial bioenergetic function across brain regions: 
Mitochondria isolated from different regions of the brain exhibit differences in 
mitochondrial bioenergetic function with the cerebellum and the striatum exhibiting 
significant differences. Compared with the striatum, the cerebellum exhibited a 36% 
slower rate of ADP dependent Complex I driven respiration. Additionally, analysis of 
maximal Complex II driven respiration revealed that the striatum was approximately 1.6 
times faster than the cerebellum.  Both the striatum and the hippocampus exhibited 
higher rates of residual oxygen consumption in the presence of the Complex V inhibitor 
Oligomycin-A compared to the cerebellum. The respiratory control ratio (RCR) was 
calculated to determine the overall health and integrity of the mitochondria and no 
significant differences were observed between any of the brain regions. Additionally, the 
RCR determinations revealed that the mitochondria utilized in these experiments were 
all healthy since the RCRs were greater than 5. 
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Figure 3.1: Regional differences exist in brain mitochondrial function. 
 
 
Mitochondrial bioenergetic analysis reveals regionally specific variations in mitochondrial 
function. A) Compared with the striatum, the cerebellum exhibited a 36% slower rate of 
Complex I driven mitochondrial oxygen consumption. B)  Similar to the Complex I 
findings, analysis of Complex II dependent oxygen consumption revealed that the 
cerebellum had a significantly slower rate of oxygen consumption. C) The striatum and 
the hippocampus exhibited nearly two-fold higher rates of oxygen consumption in the 
presence of Oligomycin-A. D) No significant differences exist between brain regions with 
respect to the mitochondrial respiratory control ratio.  
n=6/group.  *=p<0.05 with One-way ANOVA and SNK-post test; #=p<0.05 with One-way 
ANOVA and protected Fischer’s LSD 
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Effect of mitochondrial Complex I and II inhibitors on enzyme activity: 
Measurement of enzymatic activity was performed in order to determine the 
direct action of the inhibitors on their respective mitochondrial targets. Analysis of the 
effect on the Complex I specific inhibitor rotenone revealed that the concentration of 
rotenone required to inhibit 50% of enzyme activity, the IC50, ranged from 163-238pM 
and that no significant difference in the IC50 existed across brain regions (Figure 3.2).  
Further analysis of the effect of rotenone revealed that Complex I enzyme activity was 
equally affected across brain regions as the concentration of the inhibitor was increased. 
Similar to the effects of rotenone, exposure to the Complex II inhibitor malonate resulted 
in no significant differences in the calculated IC50 with values ranging from 440-580µM 
across brain regions (Figure 3.2). As the concentration of the inhibitor was increased, 
the resulting decline in Complex II enzyme activity was equal across all brain regions 
tested. 
Effect of mitochondrial Complex I and II inhibitors on oxygen consumption:  
Mitochondrial enzyme activity does not always change proportionally to 
mitochondrial oxygen consumption following treatment with a mitochondrial enzyme 
inhibitor. Direct measurement of enzymatic activity was performed following inhibitor 
administration to determine the effect of the inhibitors on their respective target 
enzymes. Baseline values for the two inhibitors were calculated from mitochondrial 
samples in the absence of inhibitor. Acute exposure to rotenone resulted in an 
immediate dose dependent reduction in mitochondrial Complex I driven oxygen 
consumption. Significant differences were observed across brain regions as a result of 
exposure to rotenone. Following exposure to 10pM rotenone the cerebellum and 
hippocampus were significantly more inhibited than the striatum or the cortex (Figure 
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3.3, *=p<0.05). The hippocampus remained more inhibited than the striatum following 
exposure to 100pM rotenone. All differences between brain regions went away at 
concentrations of rotenone 1nM and higher. Exposure to malonate resulted in a dose 
dependent decrease in mitochondrial driven oxygen consumption with no observed 
differences across brain regions.  
Figure 3.2. Mitochondrial Complex I and II inhibitors affect enzyme activity equally 
across brain regions. 
 
A) No differences were observed in the response of the different brain regions to 
Complex I enzyme inhibition. As the amount of rotenone was increased, all of the tested 
brain regions had similar percentage reductions in enzyme activity. B)  The response to 
Complex II inhibition was not significantly different across brain regions. Similar to the 
effects observed following rotenone administration, as the concentration of malonate 
was increased the various brain regions had similar decreases in enzyme activity. C) No 
significant differences were observed in the calculated IC50 values across brain regions 
and the reduction in enzyme activity in the presence of rotenone was comparable across 
all brain regions tested. The calculated IC50 values for malonate did not differ 
significantly between the brain regions tested. 
n=3-5/group. Two-way ANOVA 
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Figure 3.3: Regional differences exist in the susceptibility to rotenone but not 
malonate. 
 
A)  At low concentrations of the mitochondrial Complex I inhibitor rotenone the 
cerebellum and hippocampus are more susceptible to inhibition of oxygen consumption 
than the striatum or the cortex. As the concentration of rotenone increased, the 
differences between brain regions eventually went away. B) Exposure to the Complex II 
inhibitor malonate produced dose dependent reductions in mitochondrial oxygen 
consumption which did not differ across brain regions for a given concentration of 
inhibitor. 
n=5/group. *=p<0.05 Two-way Anova with Bonferroni post-test 
 
Time dependent inhibition of Complex I by rotenone:  
Human exposure to a toxin can occur over time frames longer than in vitro experiments 
which typically assess inhibitory values are conducted. Isolated cortical mitochondria 
treated with 10nM of the Complex I inhibitor rotenone exhibited a significant reduction in 
mitochondrial oxygen consumption immediately following exposure. Lower doses of 
rotenone, 10pM and 10fM, did not result in any reduction in oxygen consumption up to 
eight minutes following exposure. If exposure to rotenone at 10pM was allowed to 
continue a significant reduction in mitochondrial oxygen consumption became apparent 
as early as 12 minutes following exposure (Figure 3.4, *=p<0.05). The decrease in 
oxygen consumption following 10pM rotenone exposure eventually reached a 75% 
reduction in mitochondrial oxygen consumption.  
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Figure 3.4: Exposure to 10pM rotenone produces a progressive decrease in 
mitochondrial oxygen consumption.  
 
 
 
 
 
 
 
 
 
Samples which were exposed to 10nM rotenone produced an immediate reduction in 
oxygen consumption similar to previous finding. Similarly, exposure to 10fM rotenone 
resulted in no reduction in oxygen. In contrast to acute measurements rotenone 
dependent reductions in Complex I driven oxygen consumption, exposure to 10pM 
resulted in a progressive reduction in mitochondrial oxygen consumption. For at least 
eight minutes following exposure to 10pM rotenone no reduction in oxygen consumption 
was observed. As early as 12 minutes following exposure to 10pM rotenone a significant 
reduction in oxygen consumption occurred that continued to decrease with time. A 75% 
reduction in Complex I driven oxygen consumption was observed at 16 minutes post-
exposure and this level of inhibition continued beyond this time point without further 
reduction.  
n=5/group. *=p<0.05 Two-way ANOVA with Bonferroni post-test 
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Discussion: 
Regional differences have been observed in the activity of specific mitochondrial 
enzymes (Ryder, 1980, Gupta et al., 2000). Neuronal activity has been shown to play a 
direct role in the expression of mitochondrial proteins (Wong-Riley et al., 1997) and 
reductions in synaptic activity can lead to reduced Cytochrome-C levels (Nie and Wong-
Riley, 1996) and the number of mitochondria (Tieman 1985). Additionally, ischemic 
injury experiments have shown regionally different mitochondrial susceptibility to the 
injury (Sims, 1991) which could be the result of mitochondrial or cellular environment 
differences. Multiple groups have further, established that, in addition to brain region 
differences in mitochondrial function there is a significant difference between synaptic 
and non-synaptic mitochondria (Davey et al., 1997, Brown et al., 2006, Naga et al., 
2007, Pathak and Davey, 2008). Numerous factors are likely to play role in the 
differential susceptibility of mitochondria such as which region of the brain the 
mitochondria are from (Singh et al., 2010) or the cell containing the mitochondria 
(Zeevalk et al., 1997). 
In order to further elucidate the role of the mitochondria in regionally specific 
toxin susceptibility, analysis of basal mitochondrial function was performed across 
various regions of the brain. We hypothesized that regions which appear more 
susceptible to Complex I or Complex II inhibition in vivo may have reduced basal 
mitochondrial function. At the initial onset of these experiments we attempted to utilize 
TaClo, a metabolite of TCE which has been shown to produce robust inhibition of 
mitochondrial Complex I driven oxygen consumption (Janetzky et al., 1995). Though we 
were able to obtain a sample of TaClo, problems with the solubility of the compound and 
a limited amount of it precluded its use to the present studies. Given that TaClo is known 
to inhibit mitochondrial Complex I, the much more usable inhibitor rotenone was utilized 
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in these experiments for technical reasons. The results indicate that the greatest 
differences in Complex I and Complex II dependent oxygen consumption exist between 
the cerebellum and the striatum (Figure 3.1). The finding of reduced basal oxygen 
consumption in the cerebellum compared to other brain regions has not been shown 
before and therefore the underlying reason for this effect is currently unknown. Previous 
work has show a reduced activity of Complex II enzyme activity in the cerebellum 
(Fagundes et al., 2007) and this could be an underlying reason for the reduced Complex 
II dependent oxygen consumption observed in these studies. It has recently been shown 
that resting aerobic glycolysis is lower in the cerebellum than other brain regions 
(Vaishnavi et al., 2010) and this may be the result of different ratios of neuronal and non-
neuronal cells in the cerebellum (Azevedo et al., 2009). Interactions between neurons 
and astrocytes during in vivo oxygen consumption has been shown to occur (Kasischke 
et al., 2004) with the two cell types providing different roles during energy metabolism 
(for review see (Magistretti, 2006). Given the higher percentage of neurons to astrocytes 
in the cerebellum, the regional differences in the mitochondrial respiration observed in 
the present studies may be affected by different cell type ratios. Basal Complex I and 
Complex II dependent mitochondrial oxygen consumption did not differ between the 
cortex, striatum, or hippocampus in these experiments which indicates that mitochondria 
from these regions have similar bioenergetic capacities and profiles. Interestingly, the 
cerebellum had a significantly slower rate of oxygen consumption in the presence of the 
Complex V inhibitor Oligomycin-A compared to the striatum and hippocampus (Figure 
3.1B). The difference in oxygen consumption in the presence of Oligomycin-A may be 
the result of lower levels of glutathione and superoxide dismutase in the striatum and 
hippocampus relative the cerebellum (Sanchez-Iglesias et al., 2009) which could 
possibly allow for increased damage to the inner mitochondrial membrane and increased 
proton leak across the damaged membrane. Calculation of the mitochondrial Respiratory 
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Control Ratio revealed high levels of coupling between the pumping of protons across 
the inner membrane with the formation of ATP by Complex V (Figure 3.1D).  
Differences in mitochondrial spare respiratory capacity have been documented 
which may provide insight into the regional heterogeneity of in vivo mitochondrial toxin 
models. Previous reports utilizing the toxin trichloroethylene (Gash et al., 2008, Liu et al., 
2010) or 3-Nitroproionic acid (2-NP) (Beal et al., 1993) have shown that different regions 
of the brain do appear more susceptible than other regions. Mirandola showed that 
following in vitro systemic exposure to the mitochondrial Complex II inhibitor 3-NP there 
are regional differences in the susceptibility to mitochondrial permeability transition in 
mitochondria isolated from the brain. However, in isolated mitochondria in vitro treatment 
with 3-NP affected mitochondria equally across the same brain regions (Mirandola et al., 
2010). It has been suggested that one of the major reasons certain brain regions are 
more susceptible than other to a particular toxin is not the mitochondria itself but the 
environment the cells are in (Mirandola et al., 2010). Analysis of the susceptibility of 
isolated mitochondria to Complex I or Complex II inhibition indicates that there are no 
differences between brain regions with regards to the effect these toxins have on 
enzyme activity (Figure 3.2). This finding is in agreement with results looking at Complex 
II activity and the susceptibility to 3-NP where the cortex, striatum, and cerebellum had 
similar basal enzyme activities and susceptibilities to inhibition (Mirandola et al., 2010). It 
has previously been shown that the percentage inhibition of mitochondrial Complex I 
activity is correlated with the percentage reduction in mitochondrial oxygen consumption 
(Davey et al., 1998). The current results support this previous finding since the dose 
dependent reduction in mitochondrial oxygen consumption in the presence of the 
Complex I inhibitor rotenone (Figure 3.3A) is similar to of the reduction in Complex I 
enzyme activity (Figure 3.2A). The present study further extends this effect to Complex II 
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dependent oxygen consumption since the effect of the inhibitor malonate had a similar 
concentration dependent effect on oxygen consumption (Figure 3.2B) as it did on 
enzyme activity (Figure 3.3B). These results further indicate that at low concentrations of 
the inhibitor rotenone differences in the percentage reduction of oxygen consumption 
does differ between brain regions (Figure 3.3A).  
Previous unpublished experiments from our group indicated that a time 
dependent effect of rotenone on Complex I dependent mitochondrial function may exist 
at low concentrations of the inhibitor. To test if this effect was real, repetitive 
measurements were taken of mitochondrial samples treated with either 0, 10fM, 10pM, 
or 10nM rotenone. As shown in our previous experiments (Figure 3.4), the 10nM 
rotenone produced an immediate significant reduction in oxygen consumption while the 
10pM rotenone did not produce an immediate reduction in oxygen consumption (Figure 
3.4). Strikingly, continued exposure to the 10pM rotenone produced a clear time 
dependent reduction in Complex I dependent oxygen consumption which became 
significant by 12 minutes post injection and reach a 75% reduction in oxygen 
consumption by 16 minutes (Figure 3.4). This is an important finding to consider when 
attempting to determine the IC50 for a compound or comparing results from multiple 
groups which utilize different methodologies.  
These results show that there are no significant differences in basal 
mitochondrial bioenergetic function in samples isolated from the cortex, striatum, or 
hippocampus. The cerebellum did exhibit significant differences in basal mitochondrial 
function but the susceptibility to mitochondrial Complex I and Complex II inhibitors 
remained proportional to the other brain regions. Like the cerebellum, the other regions 
of the brain were relatively similar to mitochondrial enzyme inhibition except at low 
concentrations of rotenone where regional differences did become apparent. The effect 
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of rotenone on Complex I function is further shown to be significantly time dependent at 
a 10pM concentration.  
A major factor which must also be considered when interpreting these results is 
that the studies are carried out with equal amounts of purified mitochondria. These 
studies provide insight into the function of isolated mitochondria from different brain 
regions but do not give evidence for the amount of in vivo mitochondrial oxygen 
consumption across these regions. Previous reports have established that reductions in 
neuronal activity can lead to reduced numbers of mitochondria (Tieman, 1985) or 
amounts of mitochondrial proteins (Nie and Wong-Riley, 1996), which would impact the 
amount of oxygen consumption per volume of tissue and factors such as these are not 
addressed with these studies. Future experimentation should utilize techniques such as 
immunohistochemical or western blot analysis for the amount of mitochondrial proteins 
or the quantification of the number of mitochondria in order to determine regional 
differences in the amount mitochondria across brain regions. Furthermore,  positron 
emission tomography has been utilized to assess the consumption of pyruvate within the 
brain in vivo (Toyoda et al., 1989) and further investigation utilizing this technique or 
measurement of brain glucose utilization would help to further the understanding of 
regional mitochondrial differences. Utilizing in vivo techniques for the measurement of 
mitochondrial function would also allow for the determination of the effect of the various 
mitochondrial toxins directly on the intact brain regions. An additional level of in vivo 
differences which these studies do not address is the role of metabolic coupling between 
neurons and astrocytes. Evidence has accumulated which indicates coupling of energy 
processing machinery between these two cell populations in such a way that their 
metabolic processes function as a single unit (Kasischke et al., 2004) (for review see 
(Magistretti, 2006)). Considering that the mitochondria in the current experiments are no 
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longer inside individual cells, it is conceivable that the mitochondrial pathways may 
function differently in vitro compared with in vivo. By using techniques which do not 
disturb the brain regions, cells, or mitochondria it is possible that the results of these 
experiments could be significantly different than what is present presently. The major 
findings from these studies are that the mitochondrial machinery function similarly across 
brain regions, with the exception of the cerebellum. Additionally, mitochondrial Complex I 
and Complex II inhibitors equally affect different regions of the brain except for lower 
concentrations of rotenone. These studies further suggest that the observed regionally 
specific histological changes which occur following systemic exposure to a mitochondrial 
inhibitor (Beal et al., 1993, Liu et al., 2010) are not likely to be the result of regional 
differences in the individual mitochondria. 
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Chapter 4 
Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical 
tissue loss, and inflammation following traumatic brain injury. 
 
Introduction: 
Traumatic brain injury (TBI) pathology results from both a primary injury and a 
secondary injury cascade. The primary injury is due to biomechanical damage which 
results in the shearing and compression of neuronal, glial, and vascular tissue. The 
cascade of secondary injury damage, which occurs in the hours and days following the 
initial insult, is due to activation of pathophysiological cascades, consisting of complex 
biochemical and cellular pathways that influence progression of the injury, such as 
alterations in excitatory amino acids (Yamamoto et al., 1999, Rose et al., 2002), 
increased reactive oxygen species (ROS) production (Marklund et al., 2001, Hall et al., 
2004, Tavazzi et al., 2005), disruption of calcium homeostasis (Mattson and Scheff, 
1994, Xiong et al., 1997, Sullivan et al., 1999c), post-traumatic neuroinflammation 
(Morganti-Kossmann et al., 2001, Vlodavsky et al., 2006) and mitochondrial dysfunction 
(Azbill et al., 1997, Xiong et al., 1997, Sullivan et al., 1998b, Sullivan et al., 1999a, 
Sullivan et al., 1999b). As a result of these secondary injury processes, there are 
significant reductions in ATP levels (Sullivan et al., 1998a), increases in lipid 
peroxidation (Sullivan et al., 1998a), release of cytochrome c (Sullivan et al., 2002) and 
activation of apoptotic pathways (Sullivan et al., 2002),  all of which can lead to the 
initiation of cell death pathways.  Mitochondria are a major component of this secondary 
injury pathway because they function as a highly sensitive gatekeeper of cell death 
mechanisms and as the primary energy producer for the cell. As such, mitochondria play 
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a pivotal role in cerebral energy metabolism, intracellular calcium homeostasis, and ROS 
generation and detoxification.  
Following TBI, a significant disruption of mitochondrial homeostasis has been 
documented that results in a decline in cellular bioenergetics, increased mitochondrial 
ROS production and a decline in synaptic equilibrium (Azbill et al., 1997, Xiong et al., 
1997, Sullivan et al., 1998b, Sullivan et al., 1999a, Sullivan et al., 1999b). Therefore, 
following TBI, the degree of mitochondrial injury or dysfunction can be an important 
determinant of cell survival or death (for reviews see (Robertson, 2004, Sullivan et al., 
2005, Robertson et al., 2006) and therapeutic treatments designed to protect and 
stabilize the mitochondria have demonstrated the ability to reduce injury in preclinical 
studies (Sullivan et al., 2000a, Pandya et al., 2007). Although preclinical research has 
identified neuroprotective agents which target mitochondrial function, inflammation, and 
oxidative damage, attempts to move therapies into clinical usage have so far been 
unsuccessful (Schouten, 2007). Given the complexity of the secondary injury, it has 
been suggested that drugs which target multiple pathological pathways may yield more 
effective therapeutic approaches for TBI. The PPARγ agonist Pioglitazone has been 
shown to reduce inflammation (Besson et al., 2005, Chen et al., 2007a, Park et al., 
2007, Hyong et al., 2008, Kapadia et al., 2008) and oxidative damage (Chen et al., 
2007a, Yi et al., 2008), attenuate mitochondrial dysfunction (Hunter et al., 2007), and 
reduce cell death (McTigue et al., 2007, Park et al., 2007) following CNS injury. 
Pioglitazone’s ability to target multiple injury mechanisms may provide it with an 
advantage over other therapeutics for TBI which target a single secondary injury 
cascade. Treatment with Pioglitazone following LPS induced brain inflammation has 
shown the ability to prevent both mitochondrial impairment and neuronal cell loss 
(Hunter et al., 2007). The use of various PPARs has shown benefit in multiple CNS 
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injury models including spinal cord injury (SCI) (McTigue et al., 2007, Park et al., 2007), 
traumatic brain injury (TBI) (Besson et al., 2005, Chen et al., 2007a, Chen et al., 2008, 
Yi et al., 2008), and stroke (Collino et al., 2006, Allahtavakoli et al., 2009). Of the three 
known PPAR isoforms, PPARα and PPARγ have been the most well studied in CNS 
injury and have been shown to reduce lesion size both in SCI (McTigue et al., 2007, 
Park et al., 2007) and TBI (Yi et al., 2008), reduce inflammation (Besson et al., 2005, 
Chen et al., 2007a, Park et al., 2007, Hyong et al., 2008, Kapadia et al., 2008) , minimize 
oxidative damage (Chen et al., 2007a, Yi et al., 2008), spare neurons (McTigue et al., 
2007, Park et al., 2007), and preserve behavioral function (Chen et al., 2007a, McTigue 
et al., 2007, Park et al., 2007, Chen et al., 2008).  
The PPARγ agonist Pioglitazone is an FDA approved drug for diabetes treatment 
(for review see (Sood et al., 2000)) and has been utilized as a therapeutic in multiple 
animal models of CNS injury (Besson et al., 2005, Kiaei et al., 2005, Schutz et al., 2005, 
Collino et al., 2006, Chen et al., 2007a, McTigue et al., 2007, Park et al., 2007, Chen et 
al., 2008, Feng et al., 2008, Hyong et al., 2008, Sun et al., 2008, Yi et al., 2008, 
Allahtavakoli et al., 2009). Pioglitazone has been shown to more readily cross the blood 
brain barrier (BBB) than the similar drug Rosiglitazone (Berger and Moller, 2002) as well 
as partially activate the PPARα receptor (Sakamoto et al., 2000). Pioglitazone’s 
increased brain penetration and activation of two separate PPAR pathways may yield a 
greater therapeutic potential for the treatment of TBI (for review see (Kapadia et al., 
2008)). Currently, evidence exists showing that activation of either the PPARα (Chen et 
al., 2007a, Chen et al., 2008) or PPARγ (Yi et al., 2008) pathways are protective in 
models of TBI, however, no studies currently exist showing the effect of Pioglitazone 
following TBI. Because of the success of PPAR agonists in multiple models of CNS 
injury and their offer of a broad range of potentially protective properties, it is 
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hypothesized that PPAR activation by Pioglitazone will be beneficial in an animal model 
of controlled cortical impact (CCI) that has hallmarks of human TBI. The current project 
addresses the hypothesis that Pioglitazone will offer significant neuroprotection leading 
to maintenance of mitochondrial function, sparing of cortical tissue, attenuation of 
inflammation, and preservation of cognitive function following TBI. 
 
 
Methods:  
All studies were approved by the University of Kentucky Institutional Animal Care 
and Usage Committee. Male Sprague Dawley rats weighing 250 grams (Harlan 
Laboratory, IN) were utilized throughout all experiments.  
Controlled cortical impact brain injury:   
Animals were anesthetized with 2% isofluorane and placed in a Kopf stereotaxic 
frame for positioning under a pneumatic impactor (Precision Science Instruments). A 6 
mm craniotomy was performed, with a hand trephine, lateral to the central fissure on the 
left side of the skull centered between lambda and bregma. Animals in injury groups 
received a unilateral injury directly to the surface of the brain. The injury parameters 
consisted of a 1.5mm deep contusion at 3.5 meters/second for 500ms. Sham animals 
received a craniotomy but did not receive an impact to the brain. Following the injury a 
piece of Surgicel (Johnson&Johnson) sized to fit into the craniotomy was placed directly 
on the brain. The skull cap was replaced and secured in place with dental acrylic. Once 
the acrylic was allowed time to harden, the scalp incision was closed with surgical 
staples. Animals were removed from isofluorane and placed in a clean cage and 
temperature was maintained at 37oC with the use of a heating pad.  
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Pioglitazone treatment: 
Following the completion of the brain injuries, animals were randomly assigned to 
drug treatment groups. Pioglitazone and the antagonist T0070907 were prepared by 
adding 1mg of the compound to 25uL of 100% Ethanol, 1uL 38% HCl, and 25uL of 0.9% 
saline. This mixture was vortexed briefly and then 200uL of 0.9% saline was added. 
Each day, the drugs were made fresh for each set of injections. Pioglitazone or the 
PPARγ antagonist T0070907 were administered at 10mg/kg/injection. The vehicle 
administration group was administered the same solution used to dissolve the 
Pioglitazone and the antagonist. All injections were administered intraperitoneally. For 
mitochondrial analysis experiments treatments were started 15 minutes following the 
injury and depending upon the group a second injection was administered 24 hours 
later. For the behavioral and histological experiments treatment was begun 15 minutes 
after the injury and continued with subsequent injections at 24h, 48h, 72h and 96h after 
the first injection.  
Morris water maze behavioral assessment:    
Morris water maze testing was begun 10 days post-surgery and consisted of four 
trials per day for five consecutive days. The maze consisted of a dark black circular pool 
(170 cm diameter, 56 cm high) filled with water (27°C) to a depth of 30 cm. A clear 
circular Plexiglas platform 13 cm in diameter was placed 2 cm below the surface and 
served as the goal platform.  A video camera placed directly above the center of the pool 
recorded swimming performance. Each video record was processed by a video motion 
analyzer (Videomex V; Columbus Instruments, Columbus, OH). The swim speed was 
measured for each animal to ensure that observed changes were not secondary to 
impairments in motor function. For each animal, goal latency and distance traversed to 
the platform were measured for each of the four daily trials and averaged.  
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Histological analysis:  
After the completion of the behavioral testing, animals were sacrificed for 
histological analysis. Animals were anesthetized with sodium pentobarbital (Abbot 
Laboratories) and transcardially perfused with saline followed by 4% paraformaldehyde. 
The brain were removed and placed in 4% paraformaldehyde and 30% sucrose in PBS 
for 24hrs. After 24hrs the brains were transferred to a 30% sucrose PBS buffer without 
paraformaldehyde. Coronal sections 35µm thick were cut with a freezing microtome 
throughout the rostral caudal extent of the damaged cortex.  Sections were stained with 
neutral red and subjected to image analysis for lesion volume assessment. Quantitative 
assessment of cortical damage employed an unbiased stereological protocol using the 
Cavalieri method as previously described (Sullivan et al., 2000c, Sullivan et al., 2002).  
All slides were assessed blindly with respect to treatment group. For 
immunohistochemistry, sections containing regions of interest were incubated overnight 
at 4°C with a primary antibody.  The primary antibody for OX-42 (monoclonal, 1:2000, 
PharMingen, San Diego, CA) was used to detect microglia. After washes and incubation 
with an appropriate secondary antibody (Vector Laboratories, Burlingame, CA), 
immunoreactive cells were visualized by the avidin-biotin immunoperoxidase method 
(ABC kits, Vector Laboratories) with chromogen 3,3’-diaminobenzidine 
tetrahydrochloride (Sigma).  For each animal, sections at an interval of 770µm 
throughout the injured cortex were utilized for microglia. Five sections were selected for 
each animal and five non-overlapping adjacent fields of each section were selected 
which surrounded the edge of the cortical lesion. A Nikon Eclipse 80i light microscope 
with an attached Nikon microscope camera was used to obtain data images using a 
200X objective. The images were captured and imported into Simple PCI image 
processing software (Compix Inc.) for activated microglia counting.  
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Mitochondrial isolation and bioenergetic analysis:   
Cortical mitochondria were isolated using differential centrifugation, nitrogen 
disruption, and a Ficoll gradient. Animals were asphyxiated with CO2 and rapidly 
decapitated. A cortical punch encompassing the injury site was removed and 
immediately placed in ice-cold isolation buffer (215mM Mannitol, 75mM Sucrose, 0.1% 
BSA, 1mM EGTA, and 20mM HEPES at pH 7.2). Samples were homogenized and 
centrifuged at 1300xG for 3 minutes. Following the first spin the supernatant was placed 
in a fresh tube and the pellet was resuspended in isolation buffer and spun at 1300xG 
for 3min. The supernatant from the first and second spins were collected in separate 
tubes and spun at 13,000xG for 10 minutes. The pellets from both tubes was combined, 
resuspended in 400ul isolation buffer and placed in a nitrogen bomb at 1,200psi for 
10min. The pressure in the nitrogen bomb was rapidly released and the sample was 
placed as the top layer on a Ficoll separation column which consisted of a 10% Ficoll 
layer and a 7.5% Ficoll layer. The Ficoll column with sample was centrifuged at 
100,000xG for 30min at 4oC using a Beckman SW 55Ti rotor and ultra-centrifuge. The 
final mitochondrial pellet was resuspended in isolation buffer without EGTA to yield a 
final concentration of approximately 10mg/ml, and stored immediately on ice. To 
normalize the results, the protein concentrations were determined with all the samples 
on the same plate using the BCA protein assay kit and measuring absorbance at 560nm 
with a Biotek Synergy HT plate reader (Winooski, Vermont). Mitochondrial oxygen 
consumption was measured using a Clark-type electrode (Hansatech Instruments, 
Norfolk, England) in a continuously stirred, sealed chamber at 37°C as previously 
described (Sullivan et al., 2003). Isolated mitochondrial protein (100µg) was suspended 
in respiration buffer (215 mM mannitol, 75 mM sucrose, 0.1% BSA, 20 mM HEPES, 2 
mM MgCl, 2.5 mM KH2PO4 at pH 7.2) in a final chamber volume of 0.25 mL. 
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Mitochondrial bioenergetic analysis was measured by the sequential administration of 
substrates: 5mM Pyruvate, 2.5mM Malate, 150nM ADP, 1uM Oligomycin, and 1uM 
FCCP. 
Statistical analysis: 
All experiments were analyzed with a one-way ANOVA with post-hoc statistical 
analysis to determine group differences. Significance for all experiments was set at 
p<0.05. 
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Results: 
Pioglitazone protects mitochondria from injury-induced mitochondrial 
dysfunction. 
 
Following TBI there is significant damage to the mitochondria resulting in 
impaired bioenergetic function. In order to elucidate the effect of Pioglitazone on 
mitochondrial bioenergetic function, two different treatment paradigms for Pioglitazone 
administration were utilized. In the first set of animals, Pioglitazone was administered 
15min after the injury (10mg/kg) and animals were sacrificed 25hrs after the injury. In the 
second set of animals Pioglitazone was administered at 15min and 24hrs after injury 
(10mg/kg/injection) and animals were sacrificed at 25hrs after the injury. Following injury 
in both sets of animals, reductions in Pyruvate/Malate (PM), ADP, and FCCP 
(uncoupled) respiration rates were seen in vehicle treated animals (Figure 4.1, 
*=p<0.01). With only a single 15min injection there was a slight but non-significant 
increase in respiration rates following Pioglitazone treatment (Figure 4.1A); however, 
when Pioglitazone was given at both 15min and 24hrs after the injury a significant 
increase in mitochondrial function was observed (*=p<0.01, Figure 4.1B), indicating that 
under these conditions Pioglitazone treatment leads to preservation of the 
mitochondria’s ability to produce ATP.   
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Figure 4.1. Pioglitazone treatment attenuates mitochondrial dysfunction after 
traumatic brain injury. 
 
 
In order to assess the ability of Pioglitazone to prevent the mitochondrial dysfunction 
which occurs with this model of TBI, mitochondrial bioenergetic function was analyzed 1 
day following a controlled cortical impact TBI. A. Following a single injection of 
Pioglitazone (10mg/kg) 15 minutes after the injury, no improvements in mitochondrial 
function were observed. B. When Pioglitazone was administered at both at 15 minutes 
and 24 hours after the injury (10mg/kg/injection) a significant increase in mitochondrial 
bioenergetics was observed. These studies indicate that treatment with Pioglitazone at 
15 minutes and 24 hours is capable of preventing mitochondrial dysfunction following 
TBI. 
(* p<0.01 by one-way ANOVA with SNK post-test).  
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Pioglitazone treatment improves Morris water maze performance following 
traumatic brain injury. 
 
Cognitive impairment is a significant pathological outcome with both human and 
rodent cortical impact TBI. In order to assess the ability of Pioglitazone to reduce 
cognitive impairment following injury, animals were administered vehicle, Pioglitazone, 
or Pioglitazone plus the PPARγ antagonist T0070907 with an initial injection at 15 min 
post-injury and subsequent injections at 24h, 48h, 72h and 96h after the first injection.  
Pioglitazone and T0070907 were administered at 10 mg/kg at every dose. Morris water 
maze (MWM) assessments were performed 10 days post-injury and consisted of 4 days 
of trials. Following repeated measures analysis of the MWM results, a significant effect 
of day (p<0.0001) and a trend towards effect of treatment (latency p=0.0693; distance 
p=0.0648) were observed. To further elucidate the effect of Pioglitazone on MWM 
behavior and increase statistical power, groups were collapsed across days. When 
averaged across all testing days, the latency and distance to the platform showed 
significant effects. Injured vehicle-treated animals showed impairments in both distance 
(Figure 4.2A, *=p<0.05) and latency (Figure 4.2B, *=p<0.05) to the platform and 
treatment with Pioglitazone significantly improved behavior. Treatment with the PPARγ 
antagonist T0070907 and Pioglitazone together prevented the beneficial effects of 
Pioglitazone following injury (Figure 4.2 p<0.05 Sham vs. Pio+Ant) since animals given 
the antagonist with Pioglitazone performed similarly to injured vehicle-treated animals, 
indicating direct involvement of the PPARγ receptor. No significant differences in swim 
speed were observed among the treatment groups, suggesting that the differences in 
MWM performance were not related to motor deficits.  
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Figure 4.2. Pioglitazone treatment reduces cognitive impairment following 
traumatic brain injury. 
 
 
With this model of TBI there are impairments in Morris Water Maze (MWM) performance 
following the injury. Pioglitazone was administered for 5 days following the injury in order 
to determine if treatment with Pioglitazone is capable of preventing cognitive impairment 
with the MWM test. Treatment with Pioglitazone produced a significant reduction in both 
the distance and latency to find the platform following TBI. Additionally, animals which 
were also treated with the PPARγ antagonist T0070907 exhibited no preservation of 
function indicating that PPARγ receptor activation is required for Pioglitazone’s ability to 
preserve cognitive functioning.  
(* p<0.05 by one-way ANOVA).  
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Pioglitazone treatment reduces cortical damage following traumatic brain injury.  
Quantification of the cortical lesion was utilized to assess the efficacy of 
Pioglitazone to reduce the cortical tissue loss which occurs following CCI brain injury. 
Administration of Pioglitazone and the antagonist T0070907 was conducted in the same 
manner as for the behavioral analysis, with injections of 10mg/kg beginning 15 minutes 
after the injury and continuing at 24h, 48h, 72h and 96h after the first injection. A 
moderate CCI injury (1.5 mm) resulted in a significant loss of cortical tissue (Figure 4.3). 
At 16 days post-injury, the cortical contusion volume in the vehicle-treated control group 
was measured to be 5.09±0.73mm3 (Figure 4.3B). Treatment with Pioglitazone resulted 
in reduction of the lesion size by 55% to 2.27±0.27mm3 which was significantly smaller 
compared to the vehicle treated TBI group (Figure 4.3B, *=p<0.05). Co-treatment of 
Pioglitazone with the PPARγ antagonist T0070907 abolished the effect seen with 
Pioglitazone treatment alone. Animals that were treated with Pioglitazone and the 
antagonist had an average lesion size of 4.32±0.60 mm3 which was larger than the 
lesion size in the Pioglitazone group (Figure 4.3B, *=p<0.05 Pio vs. Pio+Ant), suggesting 
that the PPARγ receptor activation is involved in Pioglitazone’s ability to spare cortical 
tissue. Administration of the PPARγ antagonist alone following the injury did not affect 
the size of the cortical lesion.  
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Figure 4.3. Pioglitazone treatment reduces cortical tissue loss. 
 
Following a cortical impact brain injury there is significant loss of cortical tissue which 
occurs in the days and weeks following the injury. Pioglitazone was administered for 5 
days following a unilateral cortical contusion in order to access the ability of Pioglitazone 
to reduce cortical damage. In these studies Pioglitazone treatment reduced the size of 
the lesion which occurs in this CCI rat model of TBI. These studies also indicate that 
activation of the PPARγ receptor is required for this aspect of Pioglitazone’s 
neuroprotective function since treatment with the PPARγ antagonist blocked the 
therapeutic effect. A. Representative coronal sections stained with neutral red for 
animals treated with vehicle, Pioglitazone, or T0070907 and Pioglitazone at 16 days 
post-injury.  B. Lesion volume quantification showed a significantly reduced lesion 
volume in Pioglitazone-treated CCI animals when compared with the vehicle group and 
antagonist treatment prevented the effect (*=p<0.05, one-way ANOVA with SNK post-
test).  
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Pioglitazone attenuates the neuroinflammatory response after traumatic brain 
injury. 
 
Following TBI there is a significant increase in microglial activation and 
inflammation and Pioglitazone was administered in attempts to reduce post-injury 
inflammation. At 16 days after TBI, Pioglitazone-treated rats showed significantly fewer 
OX-42 positive cells in the injured cortex adjacent to the injury site, suggesting a 
reduction in both microglial activation and macrophage infiltration. The effect of 
Pioglitazone on inhibiting the inflammatory process was assessed by stereological 
quantification of the activated microglia. OX-42 immunoreactive cells exhibited two 
morphologies: resting microglia with small cell body and multiple thin processes and 
activated microglia with enlarged amoeboid cell body and pyknic processes. Following 
injury there was a significant increase in the number of activated microglia (p<0.05 
Figure 4.4B). In the injured cortex, the total number of activated microglia was reduced 
in the Pioglitazone-treated group compared vehicle treatment (Figure 4.4B). Compared 
with animals which received a sham injury, animals treated with Pioglitazone did not 
show a significant increase in the number OX-42 positive cells. Treatment with the 
PPARγ antagonist T0070907 did not prevent the effect of Pioglitazone on preventing the 
increase in inflammation, indicating that the effect was not dependent upon the PPARγ 
receptor. 
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Figure 4.4. Pioglitazone reduces post-injury microglial activation following 
traumatic brain injury. 
 
 
With this cortical contusion model of TBI there is significant inflammation which occurs 
following the injury. Pioglitazone was administered for 5 days following the injury in order 
to assess its ability to reduce inflammation following TBI. In this model, Pioglitazone 
attenuated the neuroinflammatory response in the injured animals. These studies also 
show that Pioglitazone does not require the PPARγ receptor in order to reduce 
inflammation following injury since treatment with the PPARγ inhibitor T0070907 did not 
block Pioglitazone’s neuroprotective effects. A. Immunohistochemistry for OX-42 was 
shown in cerebral cortex adjacent to the cortical lesion. The bottom images are high 
magnification views of the boxed regions. Scale bar = 100µm. B. Total number of 
activated microglia was counted in the cortex and a reduction in the number of activated 
microglia was found in Pioglitazone treated animals compared to vehicle treated 
animals. Compared with sham animals, Pioglitazone treated animals exhibited no 
significant increase in activated microglia.  
* p<0.05 by one-way ANOVA with SNK post-test.  
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Discussion: 
Previous reports from our group have shown that following TBI there is significant 
impairment of cortical mitochondria which begins acutely and substantially damages the 
mitochondria over the course of the first day following the injury (Pandya et al., 2007, 
Gilmer et al., 2009, Pandya et al., 2009). Interventions that are capable of protecting 
mitochondrial function following TBI have been demonstrated to reduce cortical damage 
and behavioral impairment (Scheff and Sullivan, 1999, Sullivan et al., 2000c, Pandya et 
al., 2007, Pandya et al., 2009). In the present studies, mitochondrial function was 
analyzed one day following the injury. We chose this time point based on previous 
experiments which have shown that at this time post-injury there is significant 
mitochondrial dysfunction in our model of cortical impact injury (Pandya et al., 2009). We 
found that with Pioglitazone treatment there are improvements in mitochondrial function 
which are observed in the Complex-I dependant, Pyruvate/Malate-driven, rates of 
oxygen consumption as well as the State III (ADP-present) and maximal (uncoupled) 
respiration rates, a measure of electron transport capacity/reserve (Figure 4.1B). From 
the mitochondrial experiments it can be concluded that animals treated with Pioglitazone 
maintain more functional mitochondria which are capable of producing more ATP and 
therefore providing the brain with the much needed energy source required for normal 
function as well as post-injury protective and reparative mechanisms. The mitochondrial 
data from these experiments also suggests that at least part of Pioglitazone’s ability to 
improve mitochondrial function involves a direct effect on the mitochondria since a single 
15 minute post injury injection only produced a non-significant trend towards improved 
mitochondrial bioenergetics (Figure 4.1A) while a subsequent injection of Pioglitazone 
one hour prior to analyzing the tissue resulted in a dramatic increase in mitochondrial 
bioenergetic function (Figure 4.1B). Since the improvement in mitochondrial function was 
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only observed after giving the second injection, the mitochondrial effect is most likely not 
due to only an up regulation of protein expression. Previously published in vitro 
experiments have shown that treatment with Pioglitazone can up regulate mitochondrial 
electron transport proteins, however, these changes take at least two days to produce 
significant increases in protein levels (Miglio et al., 2009).  Up regulation of mitochondrial 
protein expression is not likely the cause for the improvements in mitochondrial function 
seen in these experiments after the first 24 hours of Pioglitazone treatment, especially 
considering the rapid change in mitochondrial function observed one hour following the 
second Pioglitazone treatment. In order to help in determining whether Pioglitazone has 
a direct effect on mitochondrial function, future experiments should incorporate 
modifications to the current treatment and testing paradigm. Similar to the testing 
following the second injection of Pioglitazone at 24 hours post injury, further 
experimentation should include analysis of mitochondrial function one hour following the 
first 15 minute post injury injection. Since the majority of the Pioglitazone should be 
metabolized from the body 25 hours after a single injection, the lack of a therapeutic 
effect on mitochondrial function following the single injection paradigm could simply be 
that the Pioglitazone is no longer in the system. Treatment with Pioglitazone will likely 
produce even greater improvements in mitochondrial function at time points beyond 24 
hours when significant increases in mitochondrial proteins are likely occur. The rapid 
increase in mitochondrial function seen after the second injection of Pioglitazone may 
involve the mitochondrial outer membrane bound protein MitoNEET. Previously it has 
been shown that Pioglitazone binds to MitoNEET and stabilizes its conformational 
structure (Paddock et al., 2007) and that knocking-out the MitoNEET protein results in 
reductions in mitochondrial electron transport chain function (Wiley et al., 2007). In 
addition to Pioglitazone’s ability to rapidly increase mitochondrial function as seen in 
these studies, considering that PPAR agonist treatment leads to reductions in oxidative 
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damage (Chen et al., 2007a, Yi et al., 2008)  and inflammation (Besson et al., 2005, 
Chen et al., 2007a, Park et al., 2007, Hyong et al., 2008, Kapadia et al., 2008) following 
injury, Pioglitazone treatment will promote a less hostile cellular environment which will 
lead to reductions in secondary injury cascades that cause further mitochondrial 
dysfunction and propagate bioenergetic impairments. 
To further understand the effects of Pioglitazone following TBI, we wanted to 
determine if Pioglitazone was capable of reducing lesion volume and improving 
cognition. PPARγ agonists, in particular Pioglitazone, have been examined for protective 
properties in several models of CNS injury and disease (Sundararajan et al., 2006), 
including spinal cord injury. Following spinal cord injury,  Pioglitazone offers protection 
against the induction of inflammatory genes, astrogliosis, and microgliosis even if 
treatment is delayed for up to two hours after the injury (Park et al., 2007). The 
neuroprotective actions of Pioglitazone may be a general characteristic of PPARγ 
activation, as this phenomenon has been noted in other models of CNS injury. For 
instance, Pioglitazone treatment in murine models of Parkinson's disease promoted 
neuronal sparing within the substantia nigra (Breidert et al., 2002, Dehmer et al., 2004). 
Potent neuroprotection of motor neurons was also induced by Pioglitazone in transgenic 
mouse models of amyotrophic lateral sclerosis (Kiaei, 2008). Additionally, several 
studies have detected enhanced neuroprotection and decreased lesion sizes in animal 
models of stroke and intracerebral hemorrhage (Ou et al., 2006, Victor et al., 2006). To 
determine if any measurable effect on cognition or lesion volume was the result of 
activation of the PPARγ pathway, the selective PPARγ antagonist T0070907 was co-
administered with Pioglitazone. It has previously been shown that following TBI the injury 
causes cortical damage which correlates well with cognitive dysfunction as measured 
using the MWM (Marklund et al., 2001). From these studies it was determined that 
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Pioglitazone is capable preserving cognitive function, as determined by MWM 
assessment. It was observed at 15 days post injury that animals treated with 
Pioglitazone exhibited a decreased latency time and distance to the platform compared 
to animals treated with either vehicle or animals treated with Pioglitazone and the 
PPARγ antagonist T0070907 together (Figure 4.2). Since the PPARγ antagonist was 
able to block the protective effects of Pioglitazone on MWM function, activation of the 
PPARγ receptor is further implicated as a beneficial therapeutic strategy for TBI. 
Additionally, treatment with Pioglitazone resulted in a reduction of the size of the cortical 
lesion at 16 days post injury with the size of the cortical cavity being reduced from 
5.09±0.73mm3 (vehicle treated animals) to 2.27±0.27mm3 (Pioglitazone treated animals) 
(Figure 4.3). Similar to the MWM testing, administration of the PPARγ antagonist 
T0070907 almost completely blocked the neuroprotective benefit of Pioglitazone on 
sparing cortical tissue, indicating that activation of the PPARγ pathway is critical to 
attenuating cortical tissue loss as well as cognitive deficits. As has been observed in 
other CNS injury models, these studies show that following TBI Pioglitazone is capable 
of reducing neuronal cell loss and improving behavioral outcomes. 
It has been established that TBI is accompanied by a dramatic inflammatory 
response, which escalates over the first week post-injury and is thought to contribute to 
the secondary pathology of TBI. Multiple studies link agonism of PPARγ to the 
attenuation of inflammation (Jiang et al., 1998, Ricote et al., 1998, Drew et al., 2006), 
such that PPARγ activation influences the development and intensity of the inflammatory 
response. With the realization that inflammation plays a role in several 
neurodegenerative diseases, researchers have searched for a role of PPARγ in 
neurodegeneration. PPARγ activation regulates inflammation by decreasing the 
expression of a variety of pro-inflammatory genes such as COX-2, iNOS, and several 
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cytokines (Jiang et al., 1998, Ricote et al., 1998, Kitamura et al., 1999, Bernardo et al., 
2000) that have all been associated with inflammation-induced neurodegeneration 
(Banati et al., 1993, Przedborski et al., 1996, Minghetti and Levi, 1998, Liberatore et al., 
1999, Heneka et al., 2000, Arimoto and Bing, 2003, Vijitruth, 2006). Previously it has 
been shown that Pioglitazone protects against intrastriatal lipopolysaccharide (LPS)-
induced neurodegeneration by suppressing the inflammatory response, reducing 
oxidative damage and preventing mitochondrial dysfunction (Hunter et al., 2008, Xing et 
al., 2008). Since evidence shows that PPARγ is expressed throughout the brain (Moreno 
et al., 2004) in  neurons (Braissant et al., 1996) and glia (Cullingford et al., 1998, Heneka 
et al., 1999, Bernardo et al., 2000, Cristiano et al., 2001), it is possible that PPARγ 
agonism  will inhibit neuroinflammation and  neurodegeneration in multiple injury and 
disease states. Because of its wide range of potential therapeutic efficacy, several 
clinical trials using synthetic PPAR agonists have begun for the treatment of diseases 
involving aberrant or chronic immune/inflammatory responses (Pershadsingh et al., 
2004, Risner et al., 2006).   
To further elucidate the benefits of Pioglitazone following TBI, tissue was 
analyzed for assessment of inflammation following injury. As has been previously shown 
for other PPARα (Chen et al., 2007a, Chen et al., 2008) and PPARγ (Yi et al., 2008) 
agonists, treatment with Pioglitazone resulted in a significant reduction in inflammation 
following TBI in the present study. Following treatment with Pioglitazone, reductions in 
the number of activated microglia were observed in the area of the cortex adjacent to the 
site of the cortical lesion (Figure 4.4). In contrast to our data indicating that the effect of 
Pioglitazone on the cortical lesion and cognitive function is dependent on the PPARγ 
receptor, treatment with the PPARγ antagonist along with Pioglitazone did not prevent 
the reduction in activated microglia in these experiments. These studies indicate that 
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Pioglitazone’s ability to reduce inflammation following TBI is not dependent upon PPARγ 
receptor activation. Even though Pioglitazone is predominately a PPARγ agonist, 
Pioglitazone has been shown to also activate the PPARα receptor (Sakamoto et al., 
2000). Considering that activation of the PPARα receptor has previously been shown to 
reduce microglial activation (Xu et al., 2005) it is possible that Pioglitazone’s ability to 
reduce inflammation following TBI can be through activation of the PPARα pathway. 
Additionally, since mitochondrial dysfunction can lead to cell death and cause increases 
in inflammation, it is expected that the protective effects of pioglitazone on mitochondrial 
function (Figure 3.1B) are likely to lead to further reductions in post-injury increases in 
inflammation. Regardless of the exact mechanism(s) by which Pioglitazone leads to 
reductions in inflammation, the evidence from this study and studies in SCI (Park et al., 
2007) indicate that Pioglitazone treatment leads to significant reductions in inflammation 
following injury. In order to further the understanding of how Pioglitazone leads to a 
reduced inflammatory response following TBI, future experiments should seek to 
elucidate the role of other PPAR receptors in pioglitazone’s neuroprotective effect. As 
previously mentioned, since Pioglitazone can activate PPARα, further working utilizing 
selective PPARα inhibitors or knock-out animals are needed to determine the role of the 
pathway in pioglitazone’s ability to reduce inflammation. Since at this time only the 
PPARγ pathways can be excluded from playing a role in the anti-inflammatory actions of 
Pioglitazone it is unknown whether the effect is mediated by a different PPAR pathway 
or a completely different mechanism.  
These experiments are the first to show a therapeutic effect of Pioglitazone 
following TBI and they fit well with what has been previous shown regarding the use of 
PPAR agonists in CNS injury. As has been observed in SCI (McTigue et al., 2007), 
Pioglitazone is capable of reducing the cortical lesion and improving behavioral outcome 
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following injury. These experiments also produce similar findings to studies that have 
utilized either PPARα or PPARγ agonists following TBI that produce reductions in 
inflammation (Chen et al., 2007a, Yi et al., 2008), reduction in lesion volume (Yi et al., 
2008), and behavioral improvement (Chen et al., 2007a, Chen et al., 2008). This is the 
first report to our knowledge of any PPAR agonist showing protection of mitochondrial 
function following TBI. These experiments show that following TBI Pioglitazone is 
capable of protecting mitochondria, reducing inflammation, minimizing the cortical lesion, 
and improving cognitive function. Given the results of these experiments and considering 
that Pioglitazone has been shown to have better BBB permeability than the other 
PPAR  agonist Rosiglitazone (Berger and Moller, 2002), as well as partially activate the 
PPARα pathway  (Sakamoto et al., 2000), which has been shown to be efficacious 
following TBI (Chen et al., 2007a, Chen et al., 2008), we feel that Pioglitazone will be a 
more effective treatment for TBI than other PPAR agonists previously utilized for the 
treatment of TBI. 
Even with the success of the current studies, further work is needed before 
Pioglitazone should be considered for human clinical usage. Of significant important, the 
current studies only utilized a single dose of Pioglitazone and began administration 15 
minutes after the injury. Both a dose response study and a delayed administration study 
are needed in order to properly plan a human trial and determine if administration can be 
delayed longer than 15 minutes, which would be needed for nearly any human treatment 
window. Additionally, given the heterogeneity of human TBI it would be beneficial if 
Pioglitazone was tested in multiple different experimental TBI models. Though evidence 
from other models and similar PPAR agonists suggest that Pioglitazone would be 
effective for different types of TBIs without empirical evidence directly testing 
Pioglitazone it is unknown whether it would have any effect or even be potentially 
116 
 
detrimental to specific pathological subtypes. Without testing Pioglitazone in humans it 
will never be known whether or not it will be beneficial at treating human TBI. However, 
in order to provide any future clinical trials with the best possible chance of success 
much more research is needed regarding dosing and differences in efficacy with 
different types of TBI pathology.  
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Chapter 5 
Summary and conclusions 
 
 Further elucidating of the role of both toxins and treatments in traumatic brain 
injury will help in understanding the pathology which occurs following neurological insults 
and how to potentially intervene in order to minimize damage. Beyond just the direct and 
acute deficits which have been shown to occur after traumatic brain injury (Sullivan et 
al., 1999c, Sullivan et al., 2000a, Sullivan et al., 2000c, Sullivan et al., 2002, Sullivan et 
al., 2003), a strong link has been shown between history of a brain injury and the 
development of Parkinson’s disease later in life (Nayernouri, 1985, Bower et al., 2003). 
Though TBI is linked to PD, it is currently unknown if traumatic brain injury alone is 
capable of leading to Parkinson’s and evidence from both humans (Semchuk et al., 
1993, Carvey et al., 2006) and animals (Thiruchelvam et al., 2000a, Thiruchelvam et al., 
2000b, Thiruchelvam et al., 2002, Thiruchelvam et al., 2003, Ling et al., 2004a, Ling et 
al., 2004b, Fei and Ethell, 2008) suggests that multifactorial paradigms may play a role 
disease development.  
Like many of the environmental toxins linked to the development of PD in 
humans, trichloroethylene has been shown to produce neuropathology in animal studies 
(Gash et al., 2008, Liu et al., 2010) and human investigation has indicated a link 
between chronic TCE exposure and the development of PD (Gash et al., 2008). Studies 
utilizing dual injury paradigms should help in further understanding the development of 
PD in humans by attempting to mimic the complex history of exposures and insults 
which a person would be exposed to during his/her life. Even with evidence from dual 
injury models, much work is still needed to fully understand the complexities of disease 
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development in humans since many factors have been shown to play a role in disease 
development. 
 The studies presented here, utilizing trichloroethylene exposure followed by 
traumatic brain injury, provide an initial indication that the two insults may in fact be 
capable producing a dual injury phenotype. However, the model does not result in 
changes which mimic severe human PD. Behavioral analysis revealed that only 
following exposure to TCE and a moderate TBI was impairment with both the rotarod 
and cylinder test was present (Figure 2.1). Though behavioral dysfunction was observed 
it still remains unknown what the exact cause of the behavioral impairment is since 
various CNS and non-CNS factors can play a role in these measurements. It was 
hypothesized that following the dual injury there would be a much greater loss of 
dopamine neurons in the substantia nigra and dopaminergic impairment in the striatum 
than was observed in these studies. One month following the dual injury there was a 
loss of tyrosine hydroxylase positive neurons in the substantia nigra but the cell loss was 
only about 13-17% (Figure 2.2). Given evidence from humans (Riederer and Wuketich, 
1976, Morrish et al., 1996), this level of cell loss should not be capable of producing 
behavioral impairment independently which suggests a role for the brain injury, the dual 
injury, or both in the behavioral impairment. Additionally, no observable changes were 
observed in the striatal dopaminergic system one month following the dual injury (Figure 
2.3) which indicates that excessive loss of dopaminergic fibers and specific synaptic 
proteins has not occurred in this model. As expected for a moderate traumatic brain 
injury, there was a persistent loss of cortical tissue following the injury which was not 
affected by exposure to TCE (Figure 2.4). Mitochondrial impairment was observed in the 
striatum following two week exposure to TCE, however, the level of impairment was 
great enough with TCE alone that observing a dual injury affect was made nearly 
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impossible (Figure 2.5). Further studies utilizing a 1 week exposure to TCE showed no 
measurable decrease in mitochondrial function following either insult alone. However, 
exposure to TCE for 1 week followed by a TBI resulted in a 50% reduction in Complex I 
driven mitochondrial oxygen consumption. From the experiment utilizing the 1 week 
exposure to TCE it is further concluded that TCE and TBI can interact in a dual injury 
model and that the mitochondria play a pivotal role in the interaction. 
 Though the behavioral testing does not target a specific single pathway which the 
neurological dysfunction can be said to originate from, the data still suggests that a dual 
injury plays a role in the dysfunction. Neither exposure to TCE or TBI alone resulted in 
any measurable functional impairment but when TCE and a moderate TBI were 
combined together impairment did occur. Further experimentation is required to 
elucidate the pathological mechanisms which lead to the functional impairment. Two 
scenarios exist which could underlie the neurological changes which resulted in 
functional changes. First, the two insults could affect the same brain region(s) and this 
synergistic targeting could be responsible for the dysfunction. Second, the two insults 
could affect different regions of the brain individually and the presence of neurological 
dysfunction in these different brain regions may be the cause of the functional 
impairment. The cortex, striatum, and substantia nigra have all been shown to have 
some deficits in this model, some single insult based and some dual insult based, and 
given that all three of these regions play a role in dopaminergic function (Figure 1.5) it 
remains plausible that multiple brain regions may need to be affected in order for 
functional impairment to occur in this model.  
  In addition to indicating the possibility of a dual injury mechanism, the 
mitochondrial studies further support the notion that systemic exposure to TCE can 
result in mitochondrial impairment in the brain. Even though previous work (Gash et al., 
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2008) resulted in a different regional profile for the mitochondrial impairment than the 
present experiments, these studies utilized total purified mitochondria while previous 
work utilized synaptosomes for the mitochondrial analysis. It has been previously 
established that significant differences exist between synaptic and non-synaptic 
mitochondria in the brain (Davey et al., 1997, Brown et al., 2006, Naga et al., 2007) and 
this difference may underlie the seemingly conflicting results. Regardless, the analysis of 
the striatal mitochondria revealed a very significant impairment of mitochondrial function 
which was present in both groups exposed to TCE for 2 weeks (Figure 2.5).  
 In order to further understand the ability for TCE to produce regionally different 
mitochondrial impairment, it is important to understand regional differences in 
mitochondrial function and susceptibility to toxins. Previous animal studies (Ryder, 1980, 
Sims, 1991, Davey et al., 1997), and work utilizing animals exposed to trichloroethylene 
(Gash et al., 2008, Liu et al., 2010) or other mitochondrial toxins (Beal et al., 1993, 
Mirandola et al., 2010) have shown that regional differences in mitochondrial function 
and toxin susceptibility do exist. However, the reasons for the regional differences in 
mitochondrial dysfunction remain elusive. The present studies with naïve mitochondria 
suggest that with the exception of the cerebellum no major differences exist in 
mitochondria throughout the cortex, hippocampus, and striatum with respect to Complex 
I and Complex II dependent function (Figure 3.1). It has been established in vivo that 
different brain regions have different metabolic demands (Kennedy et al., 1976, Wong-
Riley, 1979) and neuronal activity affects the amount of mitochondria and mitochondrial 
proteins (Tieman, 1985, Nie and Wong-Riley, 1996) and these differences likely have 
little to do with the function of individual mitochondria. When the amount of mitochondria 
is controlled for by normalizing to protein content, regional differences in mitochondrial 
function are not strikingly different. This finding extends to mitochondrial Complex I and 
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Complex II inhibitors were no differences are seen in the inhibition of enzyme activity 
(Figure 3.2) and only small differences in oxygen consumption are seen at low 
concentrations, 10pM and 100pM, of rotenone (Figure 3.3). These findings suggest that 
the regional differences in mitochondrial dysfunction shown following exposure to TCE 
may not be the result of regionally different individual mitochondria. Mirandola et al. 
suggested that the regional differences in 3-NP induced changes in the susceptibility to 
mitochondrial permeability transition may be the result of regional differences in the 
environment which the mitochondria exist in (Mirandola et al., 2010). Interestingly, 
Mirandola found the striatum to be the region most susceptible to 3-NP inhibition 
(Mirandola et al., 2010) and this is the same region most affected by TCE in these 
studies. Given the lack of overt regional differences in basal function and susceptibility to 
inhibitors in purified naïve mitochondria from the cortex, hippocampus, and striatum the 
most likely conclusion is that the mitochondria are in fact functionally very similar across 
brain regions. Given that regional differences in mitochondrial function following 
exposure to TCE do exist, but the affected and non-affected mitochondria are likely the 
same, interventions which target the pathways responsible for making one region more 
susceptible than another region may be effective at ameliorating regionally specific 
deficits.  
 In addition to the possibility to target pathways which may make a specific brain 
region more susceptible to a systemic toxin, therapeutically targeting one part of a dual 
injury insult may provide the ability avoid or minimize the occurrence of functional 
impairment. Given that traumatic brain injury plays a role in our dual injury model, 
developing effective therapeutics to treat the brain injury is likely to provide two benefits. 
First, if an effective TBI therapeutic is developed TBI patients should receive benefit 
regardless of the presence of an additional insult. Second, if the patient already has an 
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initial insult or sustains a second insult later in life, effectively treating the TBI may 
prevent the development of dual insult based pathology.  
The studies utilizing Pioglitazone reveal that not only is the drug capable of 
minimizing some of the mitochondrial dysfunction, the effect is likely to involve a non-
PPARγ mediated pathway (Figure 3.1). Additionally, cognitive testing showed that 
animals treated with Pioglitazone were not significantly different than sham animals 
while vehicle treated animals were significantly different (Figure 3.2). The behavioral 
effects suggest that Pioglitazone does provide protection against cognitive impairment 
and finding an optimal dosing strategy should provide more robust cognitive benefits. 
Analysis of cortical tissue loss and increases in the number of activated microglia show 
that Pioglitazone is able to reduce both of these endpoints following TBI even though 
tissue loss was PPARγ dependent while microglial activation was not. This initial report 
of the therapeutic benefit of Pioglitazone will hopefully lead to further work which can 
help human patients who sustain a brain injury. Further work should be done to better 
understand the optimal dosing of the drug but the potential for a therapeutic benefit has 
now been shown with these studies.  
 The findings of the three separate projects come together to suggest of role for 
toxin, treatments, and brain regions following traumatic brain injury and dual injury 
models. The overall conclusion is that TCE and TBI are able to interact and produce 
behavioral dysfunction and a loss of TH-positive neurons in the substantia nigra, 
however, more work needs to be done refining the experimental model to understand 
the impact these findings have on Parkinson’s disease. The mitochondrial impairment in 
the striatum following TCE exposure is likely the result of regional differences in the 
cellular environment within the striatum which these mitochondria exist. The conclusions 
about the regional TCE effect are made possible because exposure to the complex I 
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inhibitor rotenone resulted in only small regional differences in mitochondrial oxygen 
consumption across the brain, specifically at low concentrations of 10pM and 100pM. 
Furthermore, it is hypothesized that treating a single insult in a dual injury paradigm will 
prevent the dual injury phenotype, and so effective therapeutics for one of the single 
insults are necessary to test this hypothesis. Given that Pioglitazone can attenuate 
pathology following TBI, and the role TBI plays in this dual injury model, future work may 
show if Pioglitazone is effective at attenuating deficits observed with this dual injury. The 
studies presented here should assist future research in understanding how toxins and 
treatments may affect traumatic brain injury and the role or lack thereof in regional 
mitochondrial function in affecting outcome. 
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